%PDF-1.3
%
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
11 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2019-04-26T04:17:08-07:00
2019-04-19T04:13:49+05:30
application/pdf
LRB-2019-0019-ver9-Norregaard_2P 187..194
uuid:afd3cda2-f985-4985-bc0c-297b6e5f49bf
uuid:118a4827-e8b0-4cbb-93c7-7b3870edf80e
endstream
endobj
12 0 obj
<>stream
x+ |
endstream
endobj
13 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
29 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(cancer)-310.7(will)-310.9(develop)-303.9(breast)-308.3(cancer-related)-317.5(CO)-309.4(despite)-309.6(recent)]TJ
0 -1.1174 TD
[(improvements)-427(in)-417(treatment)-423.9(such)-420.1(as)-417.9(sentinel)-426(node)-420.3(biopsy.)]TJ
7.3823 0 0 6.5614 297.4109 718.5825 Tm
(2)Tj
9.843 0 0 9.843 62.022 703.2188 Tm
[(The)-316.7(perception)-320(that)-322.6(CO)-315.1(is)-318.9(purely)-318.9(related)-316.7(to)-319.1(cancer)-322.3(has)-315.3(now)]TJ
0 -1.1116 TD
[(changed,)-389(and)-390.4(it)-388.4(is)-388(recognized)-390.2(that)-391.7(secondary)-393.3(forms)-386.6(of)-388.1(CO)]TJ
T*
[(may)-236.1(affect)-234.8(many)-231.4(patients)-236(and)-234.8(this)-234.9(study)-230.1(aims)-237.1(to)-227(examine)-237.2(this)]TJ
0 -1.1174 TD
[(in)-353.7(more)-352.3(detail.)-358.3(In)-353.5(the)-355.9(original)-350.2(study)-356.8(using)-351(the)-355.9(denition)-356.9(of)]TJ
0 -1.1116 TD
[(CO,)-220.7(the)-217.7(authors)-221.9(found)-218.6(that)-218.9(the)-217.7(overall)-217.6(prevalence)-224.3(was)-218.3(1.3)-218.7(per)]TJ
T*
[(1000)-269.4(rising)-271.6(to)-273(10.3)-271.7(per)-269.4(1000)-275.1(in)-267.3(the)-275.3(elderly)-275.2(in)-267.3(the)-275.3(health)-268.4(care)]TJ
0 -1.1174 TD
[(population,)-338.5(indicating)-342.2(a)-336.3(strong)-334.8(association)-338.2(with)-339.6(age.)]TJ
7.3823 0 0 6.5614 272.8062 641.877 Tm
(1)Tj
9.843 0 0 9.843 279.7794 637.455 Tm
(More)Tj
-22.123 -1.1116 TD
[(recently,)-327(a)-324.8(study)-322.2(using)-322.2(the)-327.1(same)-324.5(methods)-326.8(indicated)-324.8(that)-322.6(the)]TJ
T*
[(prevalence)-235.8(had)-234.9(risen)-237(to)-232.7(nearly)-233.7(4/1000.)]TJ
7.3823 0 0 6.5614 211.9747 619.9368 Tm
(3)Tj
9.843 0 0 9.843 217.9842 615.5715 Tm
[(It)-232.7(is)-232.5(known)-231(that)-236.2(there)]TJ
-15.845 -1.1174 TD
[(is)-439.9(a)-434.2(strong)-438.5(correlation)-436.4(betwe)-8.8(en)-435.3(obesity)-435.2(and)-436.4(CO,)-439.5(although)]TJ
0 -1.1116 TD
[(robust)-231.1(studies)-227.6(on)-232.6(this)-229.1(are)-230.2(required)-230.1(to)-227(establish)-231.1(the)-229.2(true)-230.3(size)-231.3(of)]TJ
T*
[(the)-281.1(problem)-280.9(and)-280.9(understand)-284(the)-281.1(mechanism)-10(s)-277.4(causing)-280.7(CO.)]TJ
7.3823 0 0 6.5614 291.0046 587.0549 Tm
(4)Tj
9.843 0 0 9.843 72 571.7479 Tm
-.0215 Tc
[(It)-356.8(ha)-6.5(s)-350.7(b)-5.3(een)-356.7(sh)-5.3(own)-356.7(t)-5.4(hat)-356.8(C)-.6(O)-357.5(h).4(as)-356.5(a)-357.8(s).6(i)-5.4(gni)-5.4(c)-6.5(ant)-356.8(i).3(mp)-5.3(act)-356.8(on)-356.7(th)-5.3(e)]TJ
-1.0137 -1.1174 TD
-.0195 Tc
[(individual,)-276.4(f)-3.3(amilies,)-282.1(and)-279.8(t)2.3(he)-280.9(he)-4.5(alth)-279.8(care)-280.9(s)-3.1(ystem.)]TJ
7.3823 0 0 6.5614 244.0062 565.1148 Tm
0 Tc
(5)Tj
9.843 0 0 9.843 250.2991 560.7495 Tm
-.0217 Tc
[(CO)-282.9(m)-6.7(o).2(st)-287.9(fre)-6.7(-)]TJ
-19.128 -1.1116 TD
-.0198 Tc
[(quently)-291.6(a)1(ffe)-4.8(c)1(ts)-291.4(limbs)-291.4(a)-4.8(nd)-291.6(is)-291.4(a)-4.8(s)2.3(sociate)-4.8(d)-285.8(w)-4.5(i)2(th)-285.8(pain,)-288.2(r)-3.6(educed)-291.6(mo-)]TJ
T*
-.0216 Tc
[(bi)-5.5(li)-5.5(ty,)-318.8(a)-.8(nd)-316.4(co)-5.4(mpli)-5.5(cat)-5.5(io)-5.4(ns)-316.2(su)-5.4(ch)-310.7(a)-6.6(s)-316.2(cel)-5.5(lul)-5.5(iti)-5.5(s)-316.2(a)-.8(nd)-316.4(wo)-5.4(und)-5.4(s,)-313(w)-6.3(h).3(ic)-6.6(h)]TJ
0 -1.1174 TD
[(ma)-6.5(y)-195.4(r)-5.3(equ)-5.3(i).3(r)-5.3(e)-196.6(h)-5.3(o).4(sp)-5.3(ita)-6.5(li)-5.4(zat)-5.4(ion)-5.3(.)-197.7(Un)-5.3(tre)-6.5(a)-.7(te)-6.5(d,)-197.7(t)-5.4(h).4(e)-202.3(c)-.7(on)-5.3(di)-5.4(tio)-5.3(n)-195.4(c)-6.5(an)-201.1(lea)-6.5(d)-195.4(t)-5.4(o)]TJ
0 -1.1116 TD
-.0205 Tc
[(elephantia)-5.5(sis)-338.2(w).6(he)-5.5(re)-333.8(the)-333.8(l)-4.4(imb)-338.4(i)1.3(nc)-5.5(rea)-5.5(s)1.6(es)-338.2(drastica)-5.5(lly)-338.4(in)-332.6(size)-339.5(with)]TJ
T*
-.0217 Tc
[(s)-5.3(i).1(gn)-5.5(ic)-6.7(a)-.9(nt)-195.7(ti)-5.6(ss)-5.3(ue)-196.8(cha)-6.7(nge)-6.7(s.)-192.2(I)-5.5(t)-190(i)-5.6(s)-195.4(pre)-6.7(d).2(ic)-6.7(ted)-195.6(t).1(h)-5.5(a)-.9(t)-195.7(C)-.8(O)-196.5(w)-.6(il)-5.6(l)-190(i)-5.6(ncr)-5.5(eas)-5.3(e)-191(i)-5.6(n)]TJ
0 -1.1174 TD
-.0193 Tc
[(the)-390.2(c)1.5(oming)-394.8(y)2.6(ears)-388.8(b)2.6(e)-4.3(cause)-390.2(of)-389(high)]TJ
13.5583 0 TD
-.0198 Tc
[(er)-395.2(ave)-4.8(r)2.2(age)-390.7(life)-390.7(e)1(xpectancy,)]TJ
-13.5583 -1.1116 TD
-.0214 Tc
[(hi)-5.3(gh)-5.2(er)-293.2(canc)-6.4(e)-.6(r)-293.2(s).7(u)-5.2(r).6(vi)-5.3(val)-293.3(r).6(a)-6.4(t).4(es)-5(,)-289.8(a)-.6(n)-5.2(d)]TJ
12.8787 0 TD
-.0196 Tc
[(increase)-286.8(i)-3.5(n)-285.6(l)-3.5(eve)-4.6(l)2.2(s)-291.2(o)2.3(f)-291.4(o)2.3(besity.)]TJ
7.3823 0 0 6.5614 297.4109 488.4093 Tm
0 Tc
(6)Tj
9.843 0 0 9.843 62.022 473.1022 Tm
-.0216 Tc
[(Ch)-5.4(ang)-5.4(e)-.8(s)-333.5(i).2(n)-333.7(d).3(e)-6.6(m)-.9(og)-5.4(rap)-5.4(h).3(ic)-6.6(s)-327.8(i)-5.5(n)-333.7(bot)-5.5(h)-328(W)-1.9(e)-6.6(s).5(t)-5.5(e)-.8(rn)-333.7(an)-5.4(d)-328(A)-6.3(si)-5.5(an)-333.7(pop)-5.4(ula)-6.6(-)]TJ
0 -1.1174 TD
-.0214 Tc
[(ti)-5.3(on)-5.2(s)-246.9(i).4(n)-5.2(d).5(ic)-6.4(ate)-248.3(t)-5.3(hat)-253(t).4(he)-254(huma)-6.4(n)-247.1(an)-5.2(d)-247.1(eco)-5.2(no)-5.2(mic)-248.3(c)-6.4(ost)-5.3(s)-246.9(of)-252.9(CO)-248(an)-5.2(d)-247.1(i).4(t)-5.3(s)]TJ
0 -1.1116 TD
-.0202 Tc
[(complica)-5.2(tions)-176.6(will)-176.9(be)-172.2(a)-178(m).5(uch)-171(l)-4.1(arge)]TJ
13.1264 0 TD
-.0215 Tc
[(r)-178.1(h).4(ea)-6.5(lt)-5.4(h)-172.3(p)-5.3(rob)-5.3(l).3(em)-179.3(in)-178.1(the)-179.3(f).5(u)-5.3(t).3(ur)-5.3(e.)]TJ
-13.1264 -1.1116 TD
-.0217 Tc
[(As)-264.5(i)-5.6(n)-258.9(o)-5.5(t).1(he)-6.7(r)-258.9(c)-6.7(oun)-5.5(tri)-5.6(e)-.9(s)-5.3(,)-261.3(kn)-5.5(owl)-5.6(e)-.9(dg)-5.5(e)-260.1(a)-6.7(bou)-5.5(t)-259.1(t)-5.6(he)-265.9(siz)-6.7(e)-260.1(o)-5.5(f)-258.9(t)-5.6(h).2(e)-265.9(p).2(r)-5.5(obl)-5.6(em)]TJ
T*
-.0215 Tc
[(in)-229.9(De)-6.5(nma)-6.5(r).5(k,)-226.5(t)-5.4(h).4(e)-231.1(t).3(yp)-5.3(es)-229.7(of)-229.9(pat)-5.4(i).3(en)-5.3(ts)]TJ
12.8614 0 TD
-.0202 Tc
[(affected,)-231(a).6(nd)-228.6(the)-224(i)1.6(m)-5.2(p)1.7(ac)-5.2(t)-223(i)1.6(t)-228.8(h)1.7(a)-5.2(s)]TJ
-12.8614 -1.1174 TD
-.0215 Tc
[(on)-276(pat)-5.4(i).3(en)-5.3(ts)-270.1(a)-6.5(n).4(d)-270.3(t)-5.4(he)-271.4(h)-5.3(eal)-5.4(th)-270.3(c)-6.5(a)-.7(re)-271.4(s)-5.1(y).4(s)-5.1(t).3(em)-271.5(a)-6.5(r).5(e)-271.4(u)-5.3(nkn)-5.3(own)-5.3(.)]TJ
1.0137 -1.1116 TD
0 Tc
[(This)-356.9(study)-356.8(formed)-354.5(part)-357(of)-353.5(an)-360.5(international)-358.3(epidemiology)]TJ
-1.0137 -1.1116 TD
[(study,)-515.7(Lymphedema)-519.3(Impact)-517.1(and)-511.3(Prevalence)-523.6(International)]TJ
0 -1.1174 TD
[(\(LIMPRINT\),)-301.6(to)-296.1(dene)-295.7(the)-298.3(prevalence)-299.2(and)-292.4(impact)-298.4(of)-295.9(CO)-297.8(in)]TJ
0 -1.1116 TD
[(health)-216.5(services)-213.6(in)-209.7(different)-214(countries)-213.9(and)-211.8(health)-216.5(care)-209.4(systems.)]TJ
T*
[(This)-310.8(study)-316.5(was)-310.4(the)-309.9(initial)-314.8(validation)-313.4(project)-315.5(undertaken)-314.1(fol-)]TJ
0 -1.1174 TD
[(lowing)-284.2(development)-282.1(of)-278.6(the)-281.1(study)-281.9(methodology.)]TJ
1.0137 -1.1116 TD
[(To)-464.2(understand)-468.3(the)-465.4(current)-465.1(scale)-469.7(of)-462.9(the)-465.4(problem)-471(within)]TJ
-1.0137 -1.1116 TD
[(health)-268.4(services)-265.4(in)-267.3(Copenhagen,)-266.7(Denmark,)-269(and)-263.6(to)-267.3(explore)-263.6(the)]TJ
T*
[(feasibility)-343.2(of)-342(using)-339.5(the)-344.4(LIMPRINT)-342.1(methodolog)-7.9(y,)-338.6(the)-338.7(study)]TJ
0 -1.1174 TD
[(was)-281.6(designed)-281.8(with)-282(three)-284.4(related)-282.1(aims:)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 72 291.5716 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 290.2676 Tm
[(to)-411.3(determine)-412.3(the)-413.5(prevalence)-414.3(of)-411.1(CO)-413(within)-411(a)-417(range)-411(of)]TJ
0 -1.1116 TD
[(health)-642.8(care)-641.4(settings)-643.5(in)-641.7(Copenhagen,)-646.8(including)-639.3(two)]TJ
0 -1.1174 TD
[(hospital)-494(inpatient)-490.8(services,)-499.3(patients)-489.4(treated)-495.2(in)-491.9(a)-491.8(spe-)]TJ
0 -1.1116 TD
[(cialist)-298.3(lymphedema)-305.1(clinic)-297.3(\(acute)-303.9(care)-295.8(based\),)-300.1(and)-304(three)]TJ
T*
[(primary)-332.7(care)-336.2(settings,)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 72 236.7495 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 235.5023 Tm
[(to)-445.8(compare)-455.9(proles)-452.1(of)-445.7(patients)-454.8(identied)-450.2(in)-451.6(different)]TJ
0 -1.1174 TD
[(settings,)-335.9(and)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 72 214.8661 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 213.5621 Tm
[(to)-440.1(explore)-442.1(the)-442.3(feasibility)-446.8(of)-439.9(undertaking)-446.7(the)-442.3(study)-443.2(to)]TJ
0 -1.1116 TD
[(inform)-278.6(the)-275.3(wider)-278.3(implementation)-281.2(of)-272.9(LIMPRINT)-284.5(during)]TJ
0 -1.1174 TD
[(the)-332.9(international)-341(roll-out)-331.7(phase.)]TJ
-.9043 -1.8201 TD
[(The)-431.9(study)-431.7(used)-431.6(the)-430.8(following)-431.6(patient)-436.6(inclusion)-431.7(and)-430.7(ex-)]TJ
-1.0137 -1.1116 TD
[(clusion)-285.4(criteria:)]TJ
1.0137 -1.1174 TD
(Inclusion)Tj
/F10 1 Tf
7.9702 0 0 7.9702 72 135.6661 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 134.3622 Tm
[(Patients)-431.6(over)-431.8(18)-428.4(years)-428.1(of)-434.1(age)-431.8(who)-424.6(had)-430.7(CO)-430.3(for)-429.5(more)]TJ
0 -1.1116 TD
[(than)-334(3)-335.2(months)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 72 113.726 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 112.422 Tm
[(Able)-334.9(to)-330.6(understand)-341.6(written)-332.6(information)-337.4(in)-336.4(Danish)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 72 102.7842 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 101.4803 Tm
[(Ab)20(le)-251.2(to)-250(gi)20.7(ve)-256.8(in)20.7(fo)20.9(rm)19.7(ed)-251(co)19.7(ns)15.3(en)19.7(t)-260.4(t)0(o)-250(p)0(a)19.7(r)0(t)20.7(i)0(c)13.8(i)0(p)20.7(a)0(t)19.5(e)-261.4(in)-250(th)20.7(e)-261.4(s)0(t)15.1(u)0(d)20.8(y)]TJ
-.9043 -1.7222 TD
(Exclusion)Tj
/F10 1 Tf
7.9702 0 0 7.9702 72 69.3921 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 68.0882 Tm
[(Patients)-333.7(who)-338.2(did)-331.7(not)-331.7(want)-334.9(to)-336.4(participate)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 72 58.4504 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 80.9008 57.1464 Tm
[(People)-337.2(under)-334.9(the)-332.9(age)-333.9(of)-336.2(18)-330.5(years)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 727.7667 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 726.5195 Tm
[(People)-337.2(who)-332.5(did)-337.5(not)-331.7(understand)-335.8(Danish)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 716.825 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 715.5211 Tm
[(Edema)-338.6(present)-332.5(for)-337.3(less)-333.6(than)-334(3)-335.2(months)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 691.1431 Tm
[(Data)-337.7(sets)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 674.7021 Tm
[(The)-714.1(development)-719.8(and)-712.9(validation)-716.5(of)-710.6(the)-718.8(LIMPRINT)]TJ
-1.0137 -1.1116 TD
[(methodolog)-7.9(y)-421.6(have)-427.2(been)-427.2(published)-425.8(separately.)]TJ
7.3823 0 0 6.5614 500.1448 668.1258 Tm
(7)Tj
9.843 0 0 9.843 508.025 663.7605 Tm
[(During)-428(the)]TJ
-19.8076 -1.1116 TD
[(study,)-348.7(the)-350.2(following)-345.2(data)-352.4(were)-347.4(captured)-352.2(using)-345.3(standardized)]TJ
0 -1.1174 TD
[(questi)-7.8(onnaires:)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 626.6833 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 625.3794 Tm
[(social)-417.9(demographics)-421(and)-419.2(care:)-418(age,)-423.8(gender,)-415.5(and)-419.2(main)]TJ
0 -1.1116 TD
[(care)-336.2(provider)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 604.7999 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 603.4959 Tm
[(presence)-295.5(and)-286.7(site)-293.6(of)-284.4(CO)-292.1(using)-287.7(a)-290.2(body)-292.4(map,)-285.6(details,)-295.9(and)]TJ
0 -1.1174 TD
[(duration)-482.5(of)-480.2(CO,)-485.6(cellulitis)-480.5(history,)-483.5(leg)-482.6(ulceration)-487.2(and)]TJ
0 -1.1116 TD
-.0164 Tc
[(wou)5.5(nds)5.7(,)-250.2(p)5.5(itt)5.4(ing)-242.1(t)-.4(est)5.4(,)-244.5(Stemmers)-241.9(sign)5.5(,)-244.5(a)-1.4(nd)-242.1(soft)5.4(/hard)-247.9(t)5.4(issu)5.5(es)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 571.918 Tm
0 Tc
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 570.614 Tm
[(classication)-456.7(of)-451.4(the)-453.8(CO)-453.4(into)-448.2(primary/sec)-11.1(ondary)-451.2(lym-)]TJ
0 -1.1174 TD
[(phedema)-335(and)-338.5(related)-334(risk)-338.4(factors)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 549.9778 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 548.6739 Tm
[(lower)-658.5(limb)-651(mobility)-655.6(status)-658.5(\(bedbound,)-653.8(chairbound,)]TJ
0 -1.1116 TD
[(walks)-335.8(with)-333.8(walking)-338.3(aid,)-336.3(or)-330.5(walks)-335.8(unaided\))]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 528.0377 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 526.7904 Tm
[(upper)-363.7(body)-367.3(mobility)-367.7(\(full)-362.8(range)-370.7(of)-365(movement,)-362.7(limited)]TJ
0 -1.1174 TD
[(range)-336.1(of)-336.2(movement,)-334(or)-336.2(normal)-331.6(function\))]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 506.1542 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 504.8503 Tm
[(obesity)-406.4(status)-405.1(\(underweight,)-406(normal)-406.5(weight,)-404(obese,)-402.7(or)]TJ
0 -1.1116 TD
[(morbidly)-338.6(obese\))]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 484.2141 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 482.9101 Tm
[(relevant)-386.9(comorbidities:)-388(diabetes)-386.7(mellitus,)-383.6(neurological)]TJ
T*
[(disorders,)-348.3(heart)-353.5(failure/ischemic)-353.4(heart)-347.8(disease,)-354.2(or)-347.7(peri-)]TJ
T*
[(pheral)-337.3(arterial)-335.2(occlusive)-341.8(disease)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 451.3322 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 450.0282 Tm
[(types)-334.9(of)-336.2(treatments)-338.4(received)-336.1(for)-337.3(CO)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 440.3904 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 439.0865 Tm
[(subjective)-348.8(control)-343.2(of)-342(swelling,)-342.8(access)-350.7(to)-342.2(specialist)-348.7(ser-)]TJ
T*
[(vice,)-338.6(and)-332.8(requirements)-340.5(for)-331.5(community)-336.3(care)]TJ
/F10 1 Tf
7.9702 0 0 7.9702 323.0361 418.4503 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 331.9369 417.1464 Tm
[(details)-338.5(of)-330.5(swelling)]TJ
-.9043 -1.5148 TD
[(As)-388.8(the)-384.7(study)-391.3(documentation)-388.1(was)-391(written)-390.2(in)-382.5(English,)-392.5(the)]TJ
-1.0137 -1.1116 TD
[(rst)-585.9(step)-581.5(involved)-580.4(ensuring)-580.1(an)-585.1(accurate)-584.9(translation)-584.9(into)]TJ
0 -1.1174 TD
[(Danish.)-288.5(This)-282(involved)-280.9(translation)-285.4(and)-280.9(back)-283.2(translation)-285.4(of)-284.4(all)]TJ
0 -1.1116 TD
[(study)-443.2(documentation.)-443.3(The)-437.6(data)-444.6(collection)-441.2(tools)-437.5(were)-445.3(then)]TJ
T*
[(piloted)-504.6(with)-500.9(10)-497.5(patients)-506.7(at)-498.8(the)-499.9(wound)-501.7(healing)-505.6(center)-499.8(by)]TJ
0 -1.1174 TD
[(general)-391.4(nurses)-387.5(to)-382.5(ensure)-388.8(that)-386(all)-384.9(questions)-385.3(were)-387.7(easily)-383.4(un-)]TJ
0 -1.1116 TD
[(derstood.)-387.7(Documenta)-9.9(tion)-384.8(was)-385.3(also)-385.6(completed)-389.3(by)-388.1(specialist)]TJ
T*
[(nurses)-312.6(on)-307.5(the)-309.9(same)-313(patients)-310.8(to)-313.4(identify)-309.8(any)-309.7(discrepancies)-313.7(in)]TJ
0 -1.1174 TD
[(the)-286.8(data)-277.6(captured)-288.9(between)-282.9(the)-281.1(groups.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 313.0582 292.6487 Tm
[(Ethical)-337.7(Issues)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 276.2078 Tm
[(The)-328.2(study)-328(was)-327.7(approved)-327.9(by)-330.5(the)-327.1(Danish)-325.4(ethics)-331.5(committee)]TJ
-1.0137 -1.1116 TD
[(j.nr:)-607.1(2007-58-0015.)-604.1(Condentiality)-612.5(and)-603.5(anonymity)-605.8(were)]TJ
T*
[(guaranteed)-303.8(to)-290.3(participants)-299.2(before)-296.9(entering)-299.3(the)-292.6(study.)-296.9(All)-292.4(pa-)]TJ
0 -1.1174 TD
[(tients)-370.8(were)-370.4(invited)-372.1(to)-370.9(participate)-368.6(in)-370.9(the)-367.5(study)-368.3(and)-367.3(received)]TJ
0 -1.1116 TD
[(verbal)-406.5(and)-401.9(written)-401.8(information.)-404.2(Patients)-402.8(unable)-400.7(to)-399.7(provide)]TJ
T*
[(consent)-217.3(were)-214.9(excluded.)-211.7(Participants)-218.4(could)-214.1(withdraw)-213.5(from)-212.9(the)]TJ
0 -1.1174 TD
[(study)-281.9(at)-285.7(any)-280.9(time.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 313.0582 188.0503 Tm
[(Study)-338.2(Setting)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 171.6094 Tm
[(The)-282.1(study)-281.9(was)-281.6(divided)-279.8(in)-284.5(two)-280.8(parts.)]TJ
0 -1.6646 TD
[(-)-502.2(A)-347.6(point)-351.4(prevalence)-351(study)-351(carried)-351.1(out)-343.3(among)-353.5(inpatients)]TJ
.8352 -1.1174 TD
[(at)-320.3(two)-315.3(acute)-325.9(hospitals)-316.3(in)-319.1(Copenhagen,)-324.2(over)-316.6(a)-319(period)-318.9(of)]TJ
0 -1.1116 TD
[(4)-335.2(days.)]TJ
-.8352 -1.1116 TD
[(-)-502.2(Patient)-499.8(identication)-502.1(from)-500.9(four)-499.7(different)-502(sites)-496.1(in)-503.4(the)]TJ
.8352 -1.1174 TD
[(Copenhagen)-274.7(area)-272.8(through)-272.8(professionals)-269.7(was)-275.9(undertaken)]TJ
0 -1.1116 TD
[(over)-437.5(a)-434.2(4-week)-436(period.)-437.5(These)-435.1(services)-438.2(were)-439.5(an)-435.3(acute-)]TJ
T*
[(based)-618.2(lymphedema)-621.9(service,)-619.3(primary)-614.9(care)-618.4(nurses)-617.9(in)]TJ
0 -1.1174 TD
[(Copenhagen,)-289.7(primary)-286.6(care)-284.3(nurses)-289.6(in)-284.5(a)-284.5(rural)-289(setting,)-289(and)]TJ
0 -1.1116 TD
[(a)-440(private)-442.2(therapy-led)-447.8(lymphedema)-443.3(service)-443.1(in)-440.1(primary)]TJ
T*
(care.)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(188)Tj
43.8494 0 TD
[(NRREGAARD)-333.5(ET)-338.7(AL.)]TJ
ET
endstream
endobj
38 0 obj
<>stream
EFKIMA+AdvP4C4E74 wR` C15AdvP4C4E74 s 3!%0; 5|#p3Lp|~zx~M~c~kqqt
endstream
endobj
42 0 obj
<>stream
/GS1 gs
BT
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
[(Hospital)-335.5(inpatient)-339.3(prevalence)-334.5(study)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 709.3416 Tm
[(In)-244.1(addition)-252.3(to)-244.2(ethical)-247.7(approval,)-250.8(permission)-249.4(was)-247(granted)-246.3(by)]TJ
-1.0137 -1.1116 TD
[(the)-379(hospital)-378.8(administrat)-10.2(ion)-372.1(to)-382.5(conduct)-378.8(the)-379(study.)-377.5(The)-380(head)]TJ
0 -1.1174 TD
[(nurse)-294.4(of)-290.2(each)-295.9(ward)-294.4(was)-293.1(informed)-293.5(in)-290.3(writin)-7.8(g)-289.1(about)-294.8(the)-292.6(study)]TJ
0 -1.1116 TD
[(and)-367.3(they)-368.6(received)-364.9(a)-365.1(plan)-368.6(for)-366.1(the)-361.7(time)-369.9(of)-365(the)-361.7(visit)-368.6(from)-362.7(the)]TJ
T*
[(research)-260.9(team.)-259.2(A)-249.6(list)-258(of)-249.8(the)-258(number)-256.6(of)-249.8(beds)-258.8(available)-256.9(at)-256.9(each)]TJ
0 -1.1174 TD
[(ward)-334.7(in)-324.9(addition)-332.9(to)-330.6(bed)-327(occupancy)-331.4(and)-332.8(a)-324.8(list)-332.9(of)-330.5(current)-326.9(pa-)]TJ
0 -1.1116 TD
[(tients)-192.3(were)-191.9(available.)-191.2(Reasons)-195(for)-187.5(patients)-195.6(not)-187.7(being)-191.1(available)]TJ
T*
[(at)-182(the)-183.1(time)-179.8(of)-180.7(the)-183.1(visit)-184.2(were)-180.4(recorded)-185(and)-183(reasons)-182.4(for)-181.8(any)-183(other)]TJ
T*
(exclusions.)Tj
1.0137 -1.1174 TD
[(In)-238.3(addition)-240.8(to)-238.5(the)-240.7(main)-237.3(inclusion)-241.7(and)-240.6(exclusion)-236.9(criteria)-243(for)]TJ
-1.0137 -1.1116 TD
[(the)-298.3(study,)-296.9(the)-298.3(team)-296.1(asked)-295.6(the)-298.3(head)-294.7(nurse)-300.2(to)-296.1(identify)-298.3(any)-292.4(pa-)]TJ
T*
[(tient)-277.8(who)-269.1(should)-271.5(not)-274.1(be)-274.1(approached)-274.8(and)-275.2(the)-269.5(reasons)-274.6(for)-273.9(this.)]TJ
0 -1.1174 TD
[(Patients)-506.5(were)-508.7(provided)-505.4(with)-500.9(written)-505.4(information)-510.2(4)-502.2(hours)]TJ
0 -1.1116 TD
[(before)-377.5(being)-369.7(approached)-372.7(for)-371.9(consent.)-376.3(Participants)-373.9(were)-370.4(in-)]TJ
T*
[(formed)-262.4(that)-259.3(they)-259.1(could)-260.2(withdraw)-259.6(from)-259(the)-263.8(study)-258.9(at)-256.9(any)-257.9(time.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 530.8723 Tm
[(Screening)-334.8(for)-338.9(CO)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 514.488 Tm
[(All)-298.2(patients)-299.3(were)-295.6(screened)-301.2(to)-290.3(identify)-298.3(the)-298.3(presence)-301.2(or)-290.2(ab-)]TJ
-1.0137 -1.1174 TD
[(sence)-285.3(of)-272.9(CO)-280.6(by)-278.7(the)-275.3(use)-280.7(of)-278.6(a)-278.7(standard)-281.7(assessment,)-283.5(the)-275.3(pitting)]TJ
0 -1.1116 TD
[(edema)-257.9(test,)-256.7(which)-255.3(measures)-255(the)-258(site)-253.3(and)-252.1(depth)-254.5(of)-255.6(swelling)-252.9(in)]TJ
T*
[(an)-360.5(edematous)-360.2(area)-359.2(when)-357.8(pressure)-362(is)-353.5(applied)-361.6(by)-353.5(the)-361.7(thumb.)]TJ
0 -1.1174 TD
[(A)-353.3(positive)-350(result)-353.4(is)-353.5(indicated)-353.6(if)-347.9(a)-353.6(pit)-349.1(remains)-351(following)-351(re-)]TJ
0 -1.1116 TD
[(moval)-376.7(of)-370.8(pressure.)-371.2(This)-374.2(is)-370.8(a)-370.9(well-established)-380.5(clinical)-375.7(tech-)]TJ
T*
[(nique,)-355.8(but)-349(inter-rater)-355.7(reliability)-360.8(was)-350.7(further)-354.5(assessed)-357.1(for)-348.8(its)]TJ
0 -1.1174 TD
[(use)-205.9(in)-203.9(the)-206.2(LIMPRINT)-209.6(study.)-204.7(Levels)-205.9(of)-203.8(agreement)-206(were)-209.2(found)]TJ
0 -1.1116 TD
[(to)-284.6(be)-291.3(high)-281(between)-288.7(general)-287.8(nurses)-289.6(performing)-289.9(the)-286.8(technique)]TJ
T*
[(and)-338.5(a)-342.1(clinical)-341.1(expert)-337.3(\(gold)-339.7(standard\))-340.4(in)-342.1(Japan.)]TJ
7.3823 0 0 6.5614 245.7637 420.2078 Tm
(8)Tj
9.843 0 0 9.843 252.7936 415.8424 Tm
[(Edema)-338.6(was)]TJ
-19.6118 -1.1174 TD
[(judged)-336.2(to)-324.9(be)-331.7(chronic)-332.7(if)-330.6(it)-330.8(had)-332.8(been)-329.3(present)-332.5(for)-331.5(3)-329.4(months)-330.3(or)]TJ
0 -1.1116 TD
(more.)Tj
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 368.9007 Tm
[(Research)-334.8(Team)-337.2(Preparation)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 352.4597 Tm
[(The)-345.5(research)-347.3(team)-342.1(consisted)-346.2(of)-342(student)-343(nurses)-347.2(who)-344(were)]TJ
-1.0137 -1.1116 TD
[(supervised)-208.9(by)-198(specialist)-210.5(teams)-204.8(from)-201.4(the)-200.4(wound)-202.2(healing)-206.1(center)]TJ
0 -1.1174 TD
[(at)-343.3(Copenhagen)-343.9(and)-338.5(visiting)-343.2(international)-346.7(lymphedema)-345.4(con-)]TJ
0 -1.1116 TD
[(sultants.)-226.5(The)-218.8(specialists)-228.6(were)-220.7(responsible)-221.6(for)-222.1(classication)-226.3(of)]TJ
T*
[(patients)-264.8(into)-258.1(a)-261.4(primary)-263.6(or)-255.6(secondary)-266.6(form)-259(of)-255.6(lymphedem)-9.1(a)-255.7(i)0(n)]TJ
T*
[(all)-338.8(cases)-342.7(identied)-340.8(with)-339.6(CO.)-341.6(Any)-338.2(participant)-344.4(for)-337.3(whom)-334.8(the)]TJ
0 -1.1174 TD
[(underlying)-311.9(classication)-312.7(of)-307.4(lymphedema)-310.8(was)-310.4(uncertain)-307.4(was)]TJ
0 -1.1116 TD
[(discussed)-340.1(within)-336.2(the)-332.9(expert)-337.3(group)-339.5(and)-332.8(a)-336.3(second)-337(clinical)-335.4(as-)]TJ
T*
[(sessment)-288.4(was)-281.6(undertaken.)]TJ
1.0137 -1.1174 TD
[(During)-191.9(the)-194.7(study)-189.8(period,)-195.6(small)-192.3(research)-197.5(teams)-193.3(were)-191.9(formed)]TJ
-1.0137 -1.1116 TD
[(with)-351.1(experts)-349.8(in)-347.9(each)-353.5(group.)-348.7(All)-350(those)-346.4(involved)-350.1(in)-347.9(data)-352.4(col-)]TJ
T*
[(lection)-263.8(were)-261(educated)-267(and)-257.9(were)-261(assessed)-264.9(to)-261.5(be)-256.8(competent)-262.6(by)]TJ
0 -1.1174 TD
[(specialists)-303.5(working)-296.7(with)-299.3(them)-294.9(during)-294.7(the)-298.3(rst)-297.9(assessment)-297.3(of)]TJ
0 -1.1116 TD
[(participants.)-233.5(Student)-222.1(nurses)-226.2(did)-222.3(not)-228.1(classify)-224.1(patients)-230.2(as)-222(cases.)]TJ
T*
[(All)-309.7(those)-306.1(involved)-304(in)-301.8(data)-306.4(collection)-308.8(received)-307.3(a)-307.5(day)-304(of)-307.4(edu-)]TJ
0 -1.1174 TD
[(cation)-285.7(and)-280.9(were)-284(assessed)-282.2(using)-281.9(a)-278.7(competenc)-10.2(y)-277.6(framework.)]TJ
1.0137 -1.1116 TD
[(The)-195.7(inpatients)-198(were)-203.4(examined)-198(over)-195.6(a)-198.1(4-day)-196.7(period)-192.2(and)-200.3(data)]TJ
-1.0137 -1.1116 TD
[(entered)-253.2(into)-246.6(a)-249.9(paper-based)-252.7(case)-249.6(report)-244(form.)-250.9(Due)-247.2(to)-250(time)-249(and)]TJ
T*
[(limited)-304.4(resources,)-298.6(a)-301.8(random)-296.9(permuted)-300.5(block)-300.5(design)-295.7(allowed)]TJ
0 -1.1174 TD
[(for)-458.3(a)-451.5(50%)-453.6(minimum)-455.2(sample)-453.6(in)-451.6(which)-456.9(additional)-457.4(clinical,)]TJ
0 -1.1116 TD
[(health-related)-424.9(quality-of-life,)-420.2(and)-419.2(disability)-421.6(data)-415.8(were)-422.3(col-)]TJ
T*
(lected.)Tj
1.0137 -1.1174 TD
[(Quality)-315.4(mechanisms)-316.2(and)-315.5(study)-310.7(monitors)-315.3(were)-312.8(in)-313.4(place)-314.4(to)]TJ
-1.0137 -1.1116 TD
[(ensure)-394.6(that)-397.5(data)-392.8(were)-393.5(complete)-393.9(before)-394.8(leaving)-396.2(the)-390.5(clinical)]TJ
T*
[(area)-365(and)-355.8(to)-359.4(avoid)-363.9(double)-359.2(counting)-361.6(of)-359.3(any)-355.8(participants)-362.6(who)]TJ
0 -1.1174 TD
[(may)-259.1(have)-260.2(moved)-261.3(wards)-255(during)-260.1(the)-258(study)-258.9(and)-257.9(may)-259.1(have)-260.2(been)]TJ
0 -1.1116 TD
[(screened)-243.6(twice.)-237(At)-239.3(the)-235(end)-240.6(of)-232.6(each)-238.3(day,)-238.3(data)-237.2(for)-239.4(the)-235(day)-240.6(were)]TJ
T*
[(checked)-306.1(by)-301.7(an)-302.9(independent)-303.9(quality)-303(monitor.)-300.6(After)-301.3(data)-306.4(cap-)]TJ
25.5097 67.9242 TD
[(ture)-322.4(was)-327.7(complete,)-322.5(they)-328.2(were)-324.4(subsequently)-326.5(entered)-328.1(into)-321.4(the)]TJ
0 -1.1174 TD
[(online)-359.4(electronic)-361.6(data)-364(system,)-357.8(which)-359(has)-361.4(additional)-359.5(quality)]TJ
0 -1.1116 TD
[(procedures)-285(to)-278.8(ensure)-285.2(complete)-284.5(and)-280.9(accurate)-285.4(data.)]TJ
7.3823 0 0 6.5614 506.6077 707.5841 Tm
(7)Tj
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 681.2786 Tm
[(Primary)-333.5(care)-332.9(and)-335.7(specialist)-335.1(lymphedema)-329.8(services)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 664.8376 Tm
[(Staff)-352.2(in)-359.4(each)-353.5(primary)-361.5(community)-353.6(nursing)-359(team)-359.4(screened)]TJ
-1.0137 -1.1116 TD
[(their)-208.5(total)-214.4(caseloads)-215.9(for)-210.6(consent)-217.3(and)-211.8(inclusion,)-210.5(irrespective)-219.6(of)]TJ
T*
[(the)-183.1(reason)-181.5(for)-187.5(needing)-183(nursing)-180.4(care.)-189.8(The)-184.2(study)-178.2(was)-183.7(carried)-189.8(out)]TJ
0 -1.1174 TD
[(by)-180.8(nurses)-180.1(with)-184.1(expert)-181.8(knowledge)-186(in)-175.1(wounds)-185.8(and)-183(CO.)-180.3(Training)]TJ
0 -1.1116 TD
[(was)-517.8(provided)-516.9(for)-521.6(all)-517.3(sites)-519.1(using)-518.1(the)-517.2(procedures)-521.1(outlined)]TJ
T*
[(above.)-379.9(A)-382.1(unique)-382.3(patient)-379.1(identication)-386.9(code)-381.1(was)-385.3(issued)-381.9(for)]TJ
T*
[(each)-244(patient)-252.3(to)-244.2(avoid)-242.9(double)-244.1(counting,)-249.8(and)-246.4(all)-246.6(questionnaires)]TJ
0 -1.1174 TD
[(were)-284(preprinted)-284.2(with)-287.8(participant)-286.8(ID)-279.5(numbers.)-284(Master)-286.2(identi-)]TJ
0 -1.1116 TD
[(er)-211.6(lists)-212.8(were)-209.2(retained)-214.1(by)-209.5(each)-215.2(service)-212.7(manager)-214(to)-215.4(ensure)-210.3(that)]TJ
T*
[(anonymity)-260.2(was)-258.6(maintained)-263.8(and)-257.9(for)-262.4(data)-260.3(protection)-261.4(purposes.)]TJ
0 -1.1174 TD
[(Two)-506.5(specialist)-510(nurses)-508.4(were)-508.7(responsible)-509.6(for)-504.3(assessing)-512.7(the)]TJ
0 -1.1116 TD
[(quality)-280(of)-278.6(data)-283.3(and)-280.9(entering)-287.8(into)-275.4(the)-286.8(international)-283.4(database.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 522.3683 Tm
[(Data)-331.3(management)-334.9(and)-335.7(statistical)-331.4(analyses)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 505.9274 Tm
[(All)-350(data)-346.7(collected)-354.8(were)-353.2(coded)-353.4(before)-348.7(being)-352.4(keyed)-353.4(into)-344.5(a)]TJ
-1.0137 -1.1116 TD
[(database)-399.3(designed)-397(for)-394.9(the)-396.3(study.)-394.8(The)-391.6(datasheet)-400.5(was)-396.8(stored)]TJ
T*
[(securely)-461.5(and)-459.5(destroyed)-467.2(after)-457.1(statistical)-465.3(analy)-8(ses)-459.1(had)-459.5(been)]TJ
0 -1.1174 TD
[(completed.)-335.1(Information)-331.5(from)-328.1(the)-332.9(database)-330.2(was)-333.4(downloaded)]TJ
0 -1.1116 TD
[(to)-301.8(an)-297.1(Excel)-308.7(le.)-301.6(This)-299.3(le)-303.9(was)-304.6(then)-299.4(uploaded)-305(into)-304.2(a)-301.8(standard)]TJ
T*
[(statistical)-327(package)-329.2(\(Stata)-325.8(12.0;)-324.8(Statcorp\).)-326.7(All)-327(analyses)-328.8(were)]TJ
0 -1.1174 TD
[(undertaken)-803.7(using)-800.3(univariate)-809.7(comparisons)-804.5(between)-807(the)]TJ
0 -1.1116 TD
[(groups.)-464.8(Continuous)-467.1(data)-467.6(were)-468.3(analyzed)-468.6(using)-466.2(a)]TJ
/F6 1 Tf
20.6485 0 TD
(t)Tj
/F5 1 Tf
.2822 0 TD
[(-test)-467.5(for)]TJ
-20.9308 -1.1116 TD
[(comparison.)-628.4(Categorical)-628.7(data)-628.9(were)-623.9(compared)-629.8(using)-627.5(the)]TJ
0 -1.1174 TD
(Pearson)Tj
/F12 1 Tf
3.4904 0 TD
(v)Tj
/F5 1 Tf
7.3823 0 0 6.5614 350.0786 411.7038 Tm
(2)Tj
9.843 0 0 9.843 356.9952 407.2818 Tm
[(test.)-320.1(Where)-326.9(numbers)-326.7(were)-324.4(small)-324.7(in)-324.9(one)-321.3(or)-324.7(more)]TJ
-4.6884 -1.1116 TD
[(cells,)-282(Fishers)-280.2(exact)-285.6(test)-282.1(was)-281.6(used.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 374.3999 Tm
[(Assessment)-334.5(of)-330.2(Feasibility)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 357.959 Tm
[(At)-187.5(completion)-199.3(of)-192.2(each)-192.2(day)-194.5(during)-191(data)-196.9(collection,)-191.3(the)-194.7(study)]TJ
-1.0137 -1.1116 TD
[(team)-180.9(met)-184.4(together)-184.2(to)-180.9(discuss)-187(any)-183(issues)-185.9(they)-178.5(had)-183(faced)-187.5(and)-183(the)]TJ
T*
[(solutions)-401.6(they)-397.4(used)-402.8(when)-398.1(necessary.)-403.5(This)-397.2(included)-403.1(assess-)]TJ
0 -1.1174 TD
[(ment)-364(of)-365(methods)-361.4(used)-368.2(to)-365.2(screen)-367(patients)-362.7(in)-365.2(busy)-367.1(ward)-363.5(set-)]TJ
0 -1.1116 TD
[(tings,)-227.9(difculties)-239.2(of)-226.8(using)-230.1(the)-235(randomization)-232.5(process,)-231.9(and)-234.9(the)]TJ
T*
[(practical)-233.8(challenges)-234.6(faced)-233.6(by)-232.6(research)-232.1(teams.)-237.1(A)-226.6(eld)-235.9(diary)-231.4(of)]TJ
0 -1.1174 TD
[(these)-186.3(issues)-191.6(was)-189.5(kept)-190(by)-186.5(the)-188.9(principal)-191.2(investigator)-188.6(who)-188.5(shared)]TJ
0 -1.1116 TD
[(the)-240.7(overall)-246.4(ndings)-243.6(with)-241.7(the)-246.5(international)-243.1(research)-249.3(team)-244.2(who)]TJ
T*
[(were)-284(able)-283.3(to)-278.8(make)-284.4(additional)-284.6(tools)-282(available)-285.7(for)-279.7(participants)]TJ
0 -1.1174 TD
[(in)-278.8(the)-281.1(wider)-284.1(research)-283.9(study.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 237.4299 Tm
(Results)Tj
/F11 1 Tf
0 -1.8336 TD
[(Hospital)-335.5(inpatient)-332.9(prevalence)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 204.548 Tm
[(Within)-452.8(the)-459.6(potential)-462(hospital)-459.4(patient)-453.9(population)-461.8(of)-457.2(578)]TJ
-1.0137 -1.1174 TD
[(patients,)-314.3(452)-308.6(were)-318.6(included)-310.9(for)-314.3(screening)-312.8(for)-314.3(CO.)-312.8(From)-310.7(the)]TJ
0 -1.1116 TD
[(total)-185.6(group,)-187.5(126/578)-192.2(patients)-189.9(were)-191.9(excluded.)-188.7(The)-190(main)-185.5(reason)]TJ
T*
[(was)-437.1(being)-433(absent)-435.1(from)-437.5(the)-436.6(ward)-432.6(at)-435.5(the)-436.6(time)-439(of)-434.1(screening)]TJ
0 -1.1174 TD
(\()Tj
/F6 1 Tf
.3341 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(76\))-337.3(or)-336.2(an)-337.4(inability)-340(to)-336.4(consent)-338.3(due)-338.5(to)-336.4(issues)-335.6(such)-339.4(as)-337.2(de-)]TJ
-1.7164 -1.1116 TD
[(mentia)-286.9(\()]TJ
/F6 1 Tf
3.3579 0 TD
(n)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(50\).)-283.2(Of)-285.3(the)-286.8(total)-283.5(participants)-287.7(\()]TJ
/F6 1 Tf
12.0954 0 TD
(n)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(452\))-280.8(who)-286.4(were)]TJ
-18.2237 -1.1116 TD
[(screened,)-517.8(177)-515.9(\(39%\))-513.4(suffered)-517.7(with)-512.4(CO)-516.7(for)-515.8(more)-513.6(than)-512.6(3)]TJ
T*
[(months)-278.5(and)-280.9(275)-279.8(\(61%\))-283(did)-279.9(not.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 105.9023 Tm
[(Lymphedema)-330.9(service)-335.3(and)-335.7(primary)-333.7(care)]TJ
0 -1.2266 TD
[(nursing)-332.4(services)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 78.463 Tm
[(A)-192(total)-191.4(of)-192.2(723)-193.4(participants)-195.5(with)-189.8(CO)-194.2(were)-197.6(identied)-191(through)]TJ
-1.0137 -1.1116 TD
[(other)-271.7(services.)-274.6(The)-270.6(specialist)-273.8(lymphedema)-276.3(service)-276(identied)]TJ
T*
[(410)-193.4(\(57%\),)-194.3(primary)-194.5(care)-197.9(nurses)-197.4(in)-192.4(Copenhagen)-199.9(identied)-196.8(253)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(VALIDATION)-340.4(STUDY)-335.9(FOR)-334(LIMPRINT)]TJ
53.0113 0 TD
(189)Tj
ET
endstream
endobj
49 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(\(35%\),)-395.8(primary)-396.1(care)-393.8(nurses)-399(in)-394(a)-393.9(rural)-392.6(setting)-395(identied)-398.4(51)]TJ
0 -1.1174 TD
[(\(7%\),)-273.8(and)-280.9(9)-271.8(\(1%\))-276.1(were)-278.3(from)-276.3(a)-273(private)-281(lymphedema)-276.3(clinic)-280(in)]TJ
0 -1.1116 TD
[(the)-281.1(community.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 62.022 680.7683 Tm
[(Comparison)-335(of)-336.7(age)-329.4(and)-335.7(gender)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 664.3274 Tm
[(Table)-262.6(1)-254.5(gives)-265.8(details)-257.9(of)-261.4(the)-258(age)-264.8(and)-257.9(gender)-262.3(of)-261.4(participants)]TJ
-1.0137 -1.1116 TD
[(in)-186.6(all)-189(groups.)-188.4(While)-187.7(age)-189.9(was)-183.7(similar)-188.8(betwe)-8.8(en)-181.9(men)-190(and)-188.8(women)]TJ
0 -1.1174 TD
[(in)-215.4(the)-217.7(lymphedema)-218.7(service)-218.4(and)-211.8(primary)-217.5(care)-221(nursing)-215(services)]TJ
0 -1.1116 TD
[(\(LSPCs\),)-318.1(there)-324.7(was)-316.2(evidence)-324.6(of)-318.9(a)-313.3(substantial)-325.6(difference)-321(be-)]TJ
T*
[(tween)-475.4(genders)-476.3(in)-474.6(the)-476.9(different)-473.2(services.)-476.2(The)-478(age)-472.2(of)-474.5(both)]TJ
0 -1.1174 TD
[(genders)-390(was)-385.3(signicantly)-384.3(higher)-388(in)-382.5(the)-384.7(inpatient)-387.1(group)-385.6(for)]TJ
0 -1.1116 TD
[(both)-269.5(women)-268(\()]TJ
/F7 1 Tf
5.5927 0 TD
(<)Tj
/F5 1 Tf
.5529 0 TD
[(0.001\))-268.1(and)-269.4(men)-264.9(\(0.006\).)-266.8(There)-268.2(was)-270.1(a)-267.2(slightly)]TJ
-6.1456 -1.1116 TD
[(higher)-560.8(proportion)-564.1(of)-560.9(women)-567.5(\(55%\))-559.4(in)-561(the)-563.3(LSPC)-559.2(group)]TJ
T*
[(compared)-347.6(with)-345.4(inpatients)-342(\(51%\),)-344(but)-343.3(this)-344.3(did)-343.3(not)-343.3(achieve)-346.6(a)]TJ
0 -1.1174 TD
[(standard)-281.7(level)-284.6(of)-278.6(statistical)-286.7(signicance)-287.4(\()]TJ
/F6 1 Tf
16.6859 0 TD
(p)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.32\).)Tj
/F11 1 Tf
8.9663 0 0 8.9663 62.022 543.2313 Tm
[(Level)-332.2(of)-336.7(obesity)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 526.7904 Tm
[(As)-325.4(would)-323.3(be)-325.9(expected,)-333.8(there)-324.7(was)-327.7(a)-324.8(proportion)-328(of)-324.7(partici-)]TJ
-1.0137 -1.1116 TD
[(pants)-375.2(who)-372.8(were)-376.2(either)-372(obese)-376.3(or)-370.8(morbidly)-373.1(obese.)-373.9(In)-370.8(the)-373.2(in-)]TJ
25.504 21.2648 TD
[(patient)-592.2(group)-587.2(and)-586.2(LSPC)-588(group,)-584.9(percentages)-593.8(of)-583.9(patients)]TJ
0 -1.1174 TD
[(consid)-7.7(ered)-231.3(to)-227(be)-233.8(obese)-232.3(or)-232.6(morbidly)-229.1(obese)-232.3(were,)-235.6(respectively,)]TJ
0 -1.1116 TD
[(37%)-511.2(and)-511.3(35%.)-508.9(Being)-508.9(underweight)-510.9(occurred)-513.3(signicantly)]TJ
T*
[(more)-225.6(in)-226.9(the)-223.5(inpatient)-225.9(group)-224.3(\(12%\))-219.6(compared)-226.6(with)-224.4(only)-223.4(4%)-222.1(in)]TJ
T*
[(the)-188.9(other)-185.3(services.)-188.2(Overall,)-193.1(there)-186.5(was)-189.4(evidence)-186.4(of)-186.5(a)-186.6(signicant)]TJ
0 -1.1174 TD
[(difference)-557.1(in)-549.5(distribution)-555(of)-549.3(BMI)-552.4(categories)-557.1(\()]TJ
/F6 1 Tf
20.0726 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
(0.001\),)Tj
-21.4607 -1.1116 TD
[(Table)-285.6(1.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 630.8786 Tm
[(Other)-340(comorbidities)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 614.4376 Tm
-.0201 Tc
[(T)-20.1(h)-.5(e)-20.1(r)-.4(e)-287.3(w)-20.1(as)-285.9(a)-287.3(h)-20.1(ig)-20.1(h)-275.7(p)-20.1(er)-20.1(c)-6.1(e)-20.1(nt)-20.1(ag)-20.1(e)-276.9(o)-20.1(f)-275.7(p)-20.1(ar)-20.1(ti)-20.1(ci)-20.1(pa)-20.1(nt)-20.1(s)-281.4(i)-20.1(n)-275.8(b)-20.1(ot)-20.1(h)-275.9(g)-20.1(ro)-20.1(up)-20.1(s)]TJ
-1.0137 -1.1116 TD
0 Tc
[(wi)14.1(th)-203.9(co)19.7(mo)19.6(rb)20.9(id)20.7(it)20.6(ie)13.8(s)-214(a)0(s)19.9(s)0(o)21(c)0(i)19.5(a)0(t)13.8(e)0(d)-205(w)0(i)19.8(t)0(h)-203.9(C)0(O)18.9(,)-216.5(Ta)18.5(bl)20.7(e)-215.4(1)0(.)-206.1(H)0(e)18.8(a)0(r)19.7(t)-220.1(fa)19.7(il)20.6(ur)20.9(e/)]TJ
T*
[(ischaemic)-332.6(heart)-324.7(disease)-327.7(was)-327.7(signicantly)-326.7(more)-329.3(prevalent)-324.7(in)]TJ
T*
[(the)-499.9(inpatient)-496.6(group)-495(\(45%)-495(vs.)-500.8(23%,)]TJ
/F6 1 Tf
15.4418 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
[(0.001\))-492.7(as)-498.5(well)-496.3(as)]TJ
-16.8299 -1.1174 TD
[(neurologica)-10.1(l)-318(disease)-322(\(18%)-316.5(vs.)-316.5(11%)]TJ
/F6 1 Tf
14.6469 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.009\).)-317.6(Similar)-321.3(non-)]TJ
-16.035 -1.1116 TD
[(signicant)-186.2(differences)-189.4(were)-180.4(noted)-185.3(for)-181.8(the)-177.4(presence)-186(of)-180.7(diabetes)]TJ
T*
[(and)-304(peripheral)-302.7(artierial)-307.6(occlusive)-301.5(disease.)-308.1(In)-301.7(these)-301.5(numbers,)]TJ
0 -1.1174 TD
[(more)-352.3(than)-357(one)-350(comorbidity)-354.7(can)-351.2(occur)-353.4(in)-347.9(the)-350.2(individual)-352.5(pa-)]TJ
0 -1.1116 TD
[(tient.)-194.8(There)-193.3(were)-191.9(signicantly)-194.3(more)-191.1(patients)-195.6(suffering)-189.5(from)-189.9(at)]TJ
T*
[(least)-462.9(one)-459.5(comorbidity)-458.4(\(including)-461.8(obesity\))-465(in)-457.3(the)-459.6(inpatient)]TJ
ET
62.022 481.153 490.167 .22678 re
f
62.022 405.864 490.167 .28348 re
f
142.809 462.274 105.392 .22678 re
f
273.713 462.274 158.06 .22678 re
f
62.022 444.586 490.167 .22675 re
f
62.022 405.921 490.167 .22678 re
f
62.022 68.542 490.167 .28348 re
f
62.022 387.212 490.167 .28345 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 112.0251 486.8219 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(1.)Tj
/F9 1 Tf
1.2496 0 TD
[(Demographic)-337.2(Details)-330.1(and)-337.8(Comorbidities)-337.2(of)-331.2(Participants)-336.3(with)-334.7(Chronic)-332.7(Edema)]TJ
/F6 1 Tf
3.0635 -1.8427 TD
[(LPCS)-8758.9(Hospital)-337.3(inpatient)-333.3(prevalence)]TJ
/F5 1 Tf
28.81 -1.8139 TD
(t)Tj
/F6 1 Tf
.6104 0 TD
[(\(df)-83.8(\))]TJ
/F5 1 Tf
6.3229 0 TD
(p)Tj
-39.5439 0 TD
(N)Tj
/F6 1 Tf
3.7027 0 TD
[(Mean)-2966(Sd)]TJ
/F5 1 Tf
10.4921 0 TD
(N)Tj
/F6 1 Tf
5.4764 0 TD
[(Mean)-4751.2(Sd)]TJ
/F5 1 Tf
-28.2629 -1.9003 TD
[(Age)-333.2(\(women\))-2595.7(390)-2853.4(66.6)-2851.1(18.4)-3985.5(90)-4631.8(76.5)-4642(11.8)-3478.7(4.90)-334.6(\(486\))]TJ
/F7 1 Tf
46.984 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-47.5368 -1.0077 TD
[(Age)-333.2(\(men\))-3813.7(325)-2853.4(66.4)-2851.1(15.3)-3985.5(87)-4631.8(71.3)-4642(12.6)-3478.7(2.75)-334.6(\(410\))-3137.6(0.006)]TJ
0 -1.0135 TD
[(Total)-6082.9(715)-12689(177)]TJ
11.1082 -1.9061 TD
(N)Tj
/F6 1 Tf
5.3036 0 TD
(%)Tj
/F5 1 Tf
10.4114 0 TD
(N)Tj
/F6 1 Tf
6.5072 0 TD
(%)Tj
/F12 1 Tf
7.8892 0 TD
(v)Tj
/F5 1 Tf
7.3837 0 0 6.5625 472.7621 397.8141 Tm
(2)Tj
/F6 1 Tf
9.845 0 0 9.845 479.7353 393.4487 Tm
[(\(df)-83.8(\))]TJ
/F5 1 Tf
5.7067 0 TD
(p)Tj
-48.1357 -1.9003 TD
(Gender)Tj
1.002 -1.0077 TD
[(Female)-6759.6(398)-4241.3(55.1)-8724.8(90)-4937.1(50.9)-5839.7(1.01)-334.6(\(1\))-3826.6(0.32)]TJ
0 -1.0135 TD
[(Male)-7654.6(325)-4241.3(44.9)-8724.8(87)-4937.1(49.1)]TJ
-1.002 -1.3129 TD
[(Total)-8593.6(723)-14220.8(177)]TJ
0 -1.0135 TD
(Obesity)Tj
1.002 -1.0135 TD
[(Underweight)-4990.6(26)-4741.3(3.6)-8723.8(21)-4937.1(12.0)-5338.7(25.00)-335.6(\(3\))]TJ
/F7 1 Tf
45.982 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.5348 -1.0135 TD
[(Normal)-331.7(weight)-3595.9(446)-4241.3(61.7)-8724.8(89)-4937.1(50.9)]TJ
0 -1.0077 TD
[(Obese)-7217.6(192)-4241.3(26.6)-8724.8(56)-4937.1(32.0)]TJ
0 -1.0135 TD
[(Morbidly)-331.6(obese)-3825(59)-4741.3(8.2)-9224.8(9)-5437.1(5.1)]TJ
-1.002 -1.3187 TD
[(Total)-8593.6(723)-14220.8(175)]TJ
0 -1.0077 TD
(Diabetes)Tj
1.002 -1.0135 TD
[(Present)-6769.6(144)-4241.3(19.9)-8724.8(43)-4937.1(24.3)-5839.7(1.65)-334.6(\(1\))-3826.6(0.198)]TJ
T*
[(Absent)-6883.6(579)-4241.3(80.1)-8229.5(134)-4932.3(75.7)]TJ
-1.002 -1.3129 TD
[(Total)-8593.6(723)-14220.8(177)]TJ
0 -1.0135 TD
[(Heart)-336.5(failure/IHD)]TJ
1.002 -1.0135 TD
[(Present)-6769.6(169)-4241.3(23.4)-8724.8(79)-4937.1(44.6)-5338.7(32.18)-335.6(\(1\))]TJ
/F7 1 Tf
45.982 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.5348 -1.0077 TD
[(Absent)-6883.6(554)-4241.3(76.6)-8724.8(98)-4937.1(55.4)]TJ
-1.002 -1.3187 TD
[(Total)-8593.6(723)-14220.8(177)]TJ
0 -1.0135 TD
[(Neurological)-339.2(disease)]TJ
1.002 -1.0077 TD
[(Present)-7270.6(79)-4240.3(10.9)-8724.8(32)-4937.1(18.1)-5839.7(6.73)-334.6(\(1\))-3826.6(0.009)]TJ
0 -1.0135 TD
[(Absent)-6883.6(644)-4241.3(89.1)-8229.5(145)-4932.3(81.9)]TJ
-1.002 -1.3129 TD
[(Total)-8593.6(723)-14220.8(177)]TJ
0 -1.0135 TD
[(Peripheral)-336.1(arterial)-340.2(disease)]TJ
1.002 -1.0135 TD
[(Present)-7270.6(61)-4741.3(8.4)-8723.8(21)-4937.1(11.9)-5839.7(2.01)-334.6(\(1\))-3826.6(0.16)]TJ
T*
[(Absent)-6883.6(662)-4241.3(91.6)-8229.5(156)-4932.3(88.1)]TJ
-1.002 -1.3129 TD
[(Total)-8593.6(723)-14220.8(177)]TJ
/F7 1 Tf
1.002 -1.0135 TD
()Tj
/F5 1 Tf
.7198 0 TD
[(one)-332.4(comorbidity)-2311.4(456)-4241.3(63.1)-8229.5(141)-4932.3(79.7)-5338.7(17.52)-335.6(\(1\))]TJ
/F7 1 Tf
45.2622 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.5348 -1.0135 TD
[(No)-331(comorbidity)-3261.6(267)-4241.3(36.9)-8724.8(36)-4937.1(20.3)]TJ
-1.002 -1.3129 TD
[(Total)-8593.6(723)-14220.8(177)]TJ
8.7511 0 0 8.7511 70.0157 56.5795 Tm
[(IHD,)-332.7(ischaemic)-331(heart)-337.2(disease;)-338.3(LPCSs,)-330.3(lymphedema)-335.6(and)-328.1(primary)-336.3(care)-334.3(services.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(190)Tj
43.8494 0 TD
[(NRREGAARD)-333.5(ET)-338.7(AL.)]TJ
ET
endstream
endobj
54 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(group)-616(compared)-612.5(with)-610.3(the)-609.4(LSPC)-616.8(group)-610.2(\(80%)-610.2(vs.)-610.2(63%,)]TJ
/F6 1 Tf
0 -1.1174 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
(0.001\).)Tj
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 691.8234 Tm
[(Classication)-335.5(of)-336.7(lymphedema)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 675.3825 Tm
[(Lymphedema)-346.5(was)-345(diagnosed)-346.2(and)-338.5(classied)-347.2(as)-343(either)-343.2(pri-)]TJ
-1.0137 -1.1116 TD
[(mary)-317.8(or)-313.2(secondary)-312.7(from)-316.6(the)-309.9(patient)-315.7(history)-313(of)-313.2(CO,)-312.8(Table)-320.2(2.)]TJ
T*
[(There)-297(was)-293.1(a)-290.2(signicantly)-297.9(higher)-290.1(percentage)-299.2(of)-290.2(patients)-299.3(with)]TJ
0 -1.1174 TD
[(primary)-326.9(lymphedema)-333.9(in)-324.9(the)-327.1(LSPC)-323.1(group)-328(\(13%)-322.2(vs.)-328(1%\).)-324.6(Of)]TJ
0 -1.1116 TD
[(the)-200.4(175)-193.4(patients)-195.6(with)-195.6(secondary)-197.5(disease)-201(in)-192.4(the)-194.7(inpatient)-197.1(study,)]TJ
T*
[(only)-499.9(1)-490.7(\(0.6%\))-493.8(had)-499.8(cancer-related)-501.8(lymphedema)-500.9(compared)]TJ
T*
[(with)-403(55)-399.6(\(9%\))-397.1(in)-399.7(the)-402(LSPC)-398(group)-402.9(\()]TJ
/F6 1 Tf
14.8024 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F5 1 Tf
.72 0 TD
[(0.001\).)-398.2(Of)-400.5(the)-402(total)]TJ
-16.1905 -1.1174 TD
[(number)-412.2(of)-411.1(patients)-414.5(with)-414.5(secondary)-410.6(disease,)-417.6(a)-411.2(signicantly)]TJ
0 -1.1116 TD
[(higher)-428.3(proportion)-425.9(had)-424.9(a)-422.7(venous)-422.3(cause)-429.3(in)-422.8(the)-425.1(LSPC)-426.8(group)]TJ
T*
[(\(69%)-304.9(vs.)-304.9(41%\),)-302.6(while)-301.5(immobility)-302.1(was)-304.6(given)-306.3(as)-302.7(the)-304.1(cause)-302.5(in)]TJ
0 -1.1174 TD
[(more)-450.3(patients)-449.1(in)-445.8(the)-442.3(inpatient)-450.5(population)-444.6(\(44%)-448.9(vs.)-443.2(18%\).)]TJ
0 -1.1116 TD
[(There)-268.2(was)-258.6(a)-261.4(substantial)-262.2(minor)-6.8(ity)-257(of)-261.4(patients)-264.8(who)-257.6(were)-266.8(given)]TJ
T*
[(other)-358.1(classications)-359.7(in)-353.7(both)-350.1(groups,)-355.4(but)-349(more)-358.1(frequently)-353.4(in)]TJ
0 -1.1174 TD
[(the)-281.1(inpatient)-283.5(study)-281.9(group)-281.9(\(23%)-281.9(vs.)-281.9(14%\).)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 510.5762 Tm
[(Location)-338.3(and)-329.4(duration)-334.5(of)-336.7(CO)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 494.1353 Tm
[(Surprisingly,)-350.7(just)-344.3(over)-351.1(6%)-343.1(of)-347.7(patients)-345.4(suffered)-350.7(from)-351.1(arm)]TJ
-1.0137 -1.1116 TD
[(CO)-251.8(in)-244.2(both)-246.4(groups)-248.3(\(Table)-252.1(3\).)-241.7(The)-247.6(difference)-251.8(between)-254.1(groups)]TJ
T*
[(became)-283.2(apparent)-277.3(when)-282.9(examining)-278.7(the)-275.3(proportion)-281.9(of)-272.9(patients)]TJ
0 -1.1174 TD
[(with)-420.2(leg)-419.3(and)-424.9(midline)-419.4(CO.)-422.2(More)-415.4(patients)-426(were)-422.3(found)-420.2(with)]TJ
0 -1.1116 TD
[(midline)-298.5(CO)-303.6(in)-296.1(the)-298.3(LSPC)-294.3(group)-299.2(\(30\))-298.1(compared)-301.5(with)-293.5(none)-299.3(in)]TJ
T*
[(the)-281.1(inpatients.)]TJ
1.0137 -1.1174 TD
[(In)-301.7(the)-304.1(inpatient)-306.5(study,)-302.6(we)-309.5(found)-299.2(that)-305.3(23%)-303.9(of)-301.7(patients)-305.1(had)]TJ
-1.0137 -1.1116 TD
[(CO)-286.3(for)-279.7(less)-281.8(than)-282.2(6)-283.3(months)-284.2(compared)-284.2(with)-282(10%)-280.8(in)-278.8(the)-286.8(LSPC)]TJ
T*
[(group.)-193.2(In)-192.2(those)-190.9(with)-189.8(a)-192.3(duration)-194.5(of)-186.5(612)-194.5(months)-186.3(and)-194.5(12)-187.6(years,)]TJ
T*
[(the)-494.2(pattern)-499.8(was)-494.7(reversed)-495.9(with)-495.1(a)-497.6(higher)-491.7(percentage)-500.7(being)]TJ
25.5097 33.4869 TD
[(present)-418.9(in)-422.8(the)-419.3(LSPC)-421(group.)-417.8(With)-421.6(longer)-416.8(duration)-424.9(of)-416.9(lym-)]TJ
0 -1.1174 TD
[(phedema,)-303.9(the)-298.3(groups)-305.9(had)-298.2(similar)-304(distribution.)-305.1(In)-301.7(both)-298.3(popu-)]TJ
0 -1.1116 TD
[(lations,)-323.5(over)-322.3(26%)-321.2(had)-321.2(suffered)-321.9(with)-322.3(swelling)-322.1(for)-320(more)-323.6(than)]TJ
T*
[(10)-278.7(years.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 664.4408 Tm
[(Infection)-334.6(and)-329.4(hospitalization)-341.1(for)-332.5(CO)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 647.9999 Tm
[(We)-184.2(found)-189.8(that)-190.1(14%)-188.7(of)-186.5(patients)-189.9(in)-186.6(the)-188.9(hospital)-188.7(prevalence)-195.5(of)]TJ
-1.0137 -1.1116 TD
[(CO)-349.7(have)-358.1(had)-350(an)-354.7(infection)-358.2(in)-353.7(the)-350.2(area)-353.4(of)-353.5(CO)-355.4(\(Table)-355.8(4\))-353.5(and)]TJ
0 -1.1174 TD
[(almost)-227.9(8%)-222.1(of)-226.8(the)-223.5(cases)-227.5(had)-223.3(this)-229.1(infection)-225.7(within)-226.7(the)-223.5(last)-230.3(year.)]TJ
1.0137 -1.1116 TD
[(In)-180.7(LSPCs,)-189.2(over)-184.1(30%)-182.9(had)-183(a)-186.6(history)-186.3(of)-180.7(infection)-191.1(in)-180.9(the)-188.9(area)-186.4(of)]TJ
-1.0137 -1.1116 TD
[(CO,)-393.4(and)-396.1(of)-399.6(the)-396.3(total)-398.7(group,)-394.8(20%)-396(experienced)-403.9(an)-395(infection)]TJ
T*
[(within)-215.2(the)-217.7(past)-212.9(year.)-217.5(The)-218.8(number)-216.3(of)-215.3(infections)-220.9(varied)-216.4(greatly,)]TJ
0 -1.1174 TD
[(with)-282(the)-281.1(majority)-282.3(experiencing)-283(one)-280.9(or)-284.4(two)-280.8(infections.)]TJ
1.0137 -1.1116 TD
[(Interestingly,)-256.5(while)-255.5(the)-252.3(number)-256.6(of)-255.6(infections)-255.4(was)-258.6(lower)-255.3(in)]TJ
-1.0137 -1.1116 TD
[(the)-223.5(inpatient)-220.1(group,)-222(nevertheless,)-228.5(they)-218.8(were)-226.4(more)-219.9(likely)-227(to)-221.2(be)]TJ
0 -1.1174 TD
[(admitted)-283.5(to)-278.8(hospital)-280.9(for)-285.5(the)-281.1(infection)-283.3(\(11/14)-277.4(vs.)-281.9(73/143\).)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 521.5746 Tm
[(Treatment)-331.3(and)-335.7(control)-331.5(of)-336.7(swelling)]TJ
/F5 1 Tf
9.843 0 0 9.843 320.8251 505.1337 Tm
[(In)-422.6(the)-425.1(LSPC)-426.8(group,)-429.4(83%)-424.8(were)-428(receiving)-428.3(some)-427.1(form)-431.8(of)]TJ
-1.0137 -1.1174 TD
[(standard)-466.1(lymphedema)-472.1(treatment.)-473.4(This)-466.3(compares)-474.1(with)-466.3(just)]TJ
0 -1.1116 TD
[(27%)-269.3(in)-267.3(the)-275.3(hospital)-269.4(group)-270.4(\(Table)-269.4(5\).)-270.5(These)-273.8(differences)-275.8(were)]TJ
T*
[(noted)-525.2(for)-533.1(multilayer)-527.7(bandaging)-530.8(\(43%)-529.6(vs.)-529.6(7%\),)-526.1(use)-528.4(of)-526.3(a)]TJ
0 -1.1174 TD
[(compression)-257.3(garment)-259(\(63%)-258.9(vs.)-253.1(23%\),)-256.5(and)-257.9(manual)-258(lymphatic)]TJ
0 -1.1116 TD
[(drainage)-283.1(\(5%)-280.8(vs.)-281.9(0%\).)]TJ
1.0137 -1.1116 TD
[(Patients)-356.8(within)-365(the)-355.9(LSPC)-363.4(group)-356.8(were)-358.9(more)-363.9(likely)-359.5(to)-359.4(ex-)]TJ
-1.0137 -1.1174 TD
[(perience)-278.5(good)-275.1(subjective)-285.4(control)-274.1(of)-278.6(their)-277.6(swelling)-281.7(compared)]TJ
0 -1.1116 TD
[(with)-224.4(inpatients)-232.5(\(67%)-230.1(vs.)-224.3(20%\).)-227.7(This)-230.2(is)-226.8(perhaps)-228.7(not)-228.1(surprising)]TJ
T*
[(given)-191.1(the)-188.9(paucity)-194.6(of)-186.5(treatments)-194.4(being)-191.1(offered)-194.2(to)-192.4(those)-190.9(patients)]TJ
T*
[(within)-278.6(the)-281.1(hospital)-286.6(study.)]TJ
ET
59.754 357.846 490.167 .22675 re
f
59.754 68.372 490.167 .28348 re
f
151.2 338.967 69.165 .22675 re
f
257.556 338.967 150.236 .22675 re
f
59.754 321.279 490.167 .22675 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 148.7622 363.5149 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(2.)Tj
/F9 1 Tf
1.2496 0 TD
[(Causes)-335.8(of)-337(Lymphedema)-337.3(in)-331.6(Participants)-336.3(with)-334.7(Chronic)-332.7(Edema)]TJ
/F6 1 Tf
-13.2907 -3.6567 TD
(Classication)Tj
11.6323 1.8139 TD
[(LPCS)-7710.9(Hospital)-331.6(inpatient)-339(prevalence)]TJ
/F12 1 Tf
27.998 -1.8139 TD
(v)Tj
/F5 1 Tf
7.3837 0 0 6.5625 454.8471 331.8802 Tm
(2)Tj
/F6 1 Tf
9.845 0 0 9.845 461.8204 327.5149 Tm
[(\(df)-83.8(\))]TJ
/F5 1 Tf
7.1291 0 TD
(p)Tj
-38.2886 0 TD
(N)Tj
/F6 1 Tf
5.3439 0 TD
(%)Tj
/F5 1 Tf
7.5149 0 TD
(N)Tj
/F6 1 Tf
9.4613 0 TD
(%)Tj
/F5 1 Tf
-32.0002 -1.9003 TD
[(Primary)-6562.5(94)-3773.8(13.0)-6836(2)-8391.2(1.1)-5833(21.02)-335.6(\(1\))]TJ
/F7 1 Tf
46.65 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-47.2028 -1.0077 TD
[(Secondary)-5062.5(629)-3774.8(87)-6584(175)-7892.2(98.9)]TJ
0 -1.0135 TD
[(Total)-7165.5(723)-11358.8(177)]TJ
T*
(Cancer)Tj
1.002 -1.0135 TD
[(Present)-5842.5(55)-4274.8(8.7)-6835(1)-8391.2(0.6)]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
7.3837 0 0 6.5625 546.6329 273.3731 Tm
(a)Tj
9.845 0 0 9.845 69.6189 259.0298 Tm
[(Absent)-5455.5(574)-3774.8(91.3)-5834(174)-7892.2(99.4)]TJ
-1.002 -1.3187 TD
[(Total)-7165.5(629)-11358.8(175)]TJ
0 -1.0077 TD
(Venous)Tj
1.002 -1.0135 TD
[(Present)-5341.5(437)-3774.8(69.4)-6335(71)-7891.2(40.6)-5834(49.17)-335.6(\(1\))]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.2008 -1.0135 TD
[(Absent)-5455.5(192)-3774.8(30.5)-5834(104)-7892.2(59.4)]TJ
-1.002 -1.313 TD
[(Total)-7165.5(629)-11358.8(175)]TJ
0 -1.0135 TD
(Immobility)Tj
1.002 -1.0135 TD
[(Present)-5341.5(111)-3774.8(17.7)-6335(77)-7891.2(44.0)-5834(53.07)-335.6(\(1\))]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.2008 -1.0135 TD
[(Absent)-5455.5(518)-3774.8(82.3)-6335(98)-7891.2(56.0)]TJ
-1.002 -1.3129 TD
[(Total)-7165.5(629)-11358.8(175)]TJ
0 -1.0135 TD
(Obesity)Tj
1.002 -1.0077 TD
[(Present)-5341.5(125)-3774.8(19.9)-6335(42)-7891.2(24.0)-6335(1.42)-334.6(\(1\))-4327.6(0.23)]TJ
0 -1.0135 TD
[(Absent)-5455.5(504)-3774.8(80.1)-5834(133)-7892.2(76.0)]TJ
-1.002 -1.3187 TD
[(Total)-7165.5(629)-11358.8(175)]TJ
0 -1.0077 TD
(Other)Tj
1.002 -1.0135 TD
[(Present)-5842.5(87)-3773.8(13.8)-6335(40)-7891.2(22.9)-6335(8.39)-334.6(\(1\))-4327.6(0.004)]TJ
T*
[(Absent)-5455.5(542)-3774.8(86.2)-5834(135)-7892.2(77.1)]TJ
-1.002 -1.3129 TD
[(Total)-7165.5(629)-11358.8(175)]TJ
6.5633 0 0 5.8334 67.748 60.4913 Tm
(a)Tj
8.7511 0 0 8.7511 70.696 56.5795 Tm
[(Fishers)-334.2(exact)-333.3(test.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(VALIDATION)-340.4(STUDY)-335.9(FOR)-334(LIMPRINT)]TJ
53.0113 0 TD
(191)Tj
ET
endstream
endobj
58 0 obj
<>stream
0 0 0 rg
/GS1 gs
62.022 719.49 490.167 .22668 re
f
62.022 423.042 490.167 .22675 re
f
180.34 700.611 63.779 .22681 re
f
275.924 700.611 144.85 .22681 re
f
62.022 682.923 490.167 .22675 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 112.7055 725.1588 Tm
0 Tc
0 Tw
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(3.)Tj
/F9 1 Tf
1.2496 0 TD
[(Location)-338.1(and)-332(Duration)-339.1(of)-331.2(Lymphedema)-337.3(in)-331.6(Participants)-336.3(with)-334.7(Chronic)-338.5(Edema)]TJ
/F6 1 Tf
4.6932 -1.8427 TD
[(LPCS)-6616.8(Hospital)-331.6(inpatient)-339(prevalence)]TJ
/F12 1 Tf
26.0862 -1.8197 TD
(v)Tj
/F5 1 Tf
7.3837 0 0 6.5625 462.5007 693.5242 Tm
(2)Tj
/F6 1 Tf
9.845 0 0 9.845 469.4739 689.1022 Tm
[(\(df)-83.8(\))]TJ
/F5 1 Tf
6.582 0 TD
(p)Tj
-35.559 0 TD
(N)Tj
/F6 1 Tf
4.7969 0 TD
(%)Tj
/F5 1 Tf
6.8469 0 TD
(N)Tj
/F6 1 Tf
8.9142 0 TD
(%)Tj
/F5 1 Tf
-32.9677 -1.8946 TD
[(Arm)-333.2(\(s\))]TJ
1.002 -1.0135 TD
[(Present)-8572.1(46)-3727.8(6.4)-5666(11)-8098.5(6.2)-5159.2(0.005)-335.6(\(1\))-3780.6(0.94)]TJ
0 -1.0077 TD
[(Absent)-8185.1(677)-3233.5(93.6)-5160.2(166)-7598.5(93.8)]TJ
-1.002 -1.0135 TD
[(Total)-9895.1(723)-10143.8(177)]TJ
T*
[(Leg)-333.5(\(s\))]TJ
1.002 -1.0135 TD
[(Present)-8071.1(683)-3233.5(94.5)-5160.2(176)-7598.5(99.4)-12692.4(0.002)]TJ
7.3837 0 0 6.5625 548.9006 625.0392 Tm
(a)Tj
9.845 0 0 9.845 71.8866 610.6959 Tm
[(Absent)-8686.1(40)-3727.8(5.5)-6167(1)-8097.5(0.6)]TJ
-1.002 -1.3187 TD
[(Total)-9895.1(723)-10143.8(177)]TJ
0 -1.0135 TD
(Midline)Tj
1.002 -1.0077 TD
[(Present)-8572.1(30)-3727.8(4.2)-6167(0)-8097.5(0.0)-12691.4(0.002)]TJ
7.3837 0 0 6.5625 548.9006 582.1794 Tm
(a)Tj
9.845 0 0 9.845 71.8866 567.8361 Tm
[(Absent)-8185.1(693)-3233.5(95.9)-5160.2(177)-7097.5(100.0)]TJ
-1.002 -1.3129 TD
[(Total)-9895.1(723)-10143.8(177)]TJ
0 -1.0135 TD
(Duration)Tj
/F7 1 Tf
1.002 -1.0135 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
[(6)-329.2(months)-7188(74)-3232.5(10.2)-5661.2(40)-7597.5(22.6)-5160.2(29.10)-335.6(\(5\))]TJ
/F7 1 Tf
45.0952 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.2008 -1.0135 TD
[(6)-329.2(months)-335.3(to)-336.2(1)-329.2(year)-3732.1(97)-3232.5(13.4)-5661.2(13)-8098.5(7.3)]TJ
0 -1.0077 TD
[(12)-331.2(years)-7072.9(126)-3233.5(17.4)-5661.2(16)-8098.5(9.0)]TJ
0 -1.0135 TD
[(25)-331.2(years)-7072.9(152)-3233.5(21.0)-5661.2(33)-7597.5(18.6)]TJ
T*
[(510)-332.2(years)-7072.9(88)-3232.5(12.2)-5661.2(26)-7597.5(14.7)]TJ
T*
(10)Tj
/F7 1 Tf
.9962 0 TD
(+)Tj
/F5 1 Tf
.8868 0 TD
[(years)-7021(186)-3233.5(25.7)-5661.2(49)-7597.5(27.7)]TJ
-2.885 -1.313 TD
[(Total)-9895.1(723)-10143.8(176)]TJ
0 -1.0135 TD
[(Control)-336.5(of)-330.2(swelling)]TJ
1.002 -1.0077 TD
[(Yes)-9466.1(469)-3233.5(66.7)-5661.2(35)-7597.5(19.9)-5160.2(126.2)-335.6(\(1\))]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.2008 -1.0135 TD
[(No)-9798.1(234)-3233.5(33.3)-5160.2(141)-7598.5(80.1)]TJ
-1.002 -1.3187 TD
[(Total)-9895.1(703)-10143.8(176)]TJ
6.5633 0 0 5.8334 70.0157 415.1054 Tm
(a)Tj
8.7511 0 0 8.7511 72.9637 411.1936 Tm
[(Fishers)-334.2(exact)-333.3(test.)]TJ
ET
62.022 343.049 490.167 .28348 re
f
62.022 56.58 490.167 .22678 re
f
129.713 324.17 74.608 .28348 re
f
246.898 324.17 155.622 .28348 re
f
62.022 306.482 490.167 .28345 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 179.1496 348.718 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(4.)Tj
/F9 1 Tf
1.2496 0 TD
[(Infections)-335.7(in)-331.6(Participants)-336.3(with)-334.7(Chronic)-332.7(Edema)]TJ
/F6 1 Tf
-6.6511 -1.837 TD
[(LPCS)-8805(Hospital)-337.3(inpatient)-333.3(prevalence)]TJ
/F12 1 Tf
29.9214 -1.8197 TD
(v)Tj
/F5 1 Tf
7.3837 0 0 6.5625 455.0172 317.0834 Tm
(2)Tj
/F6 1 Tf
9.845 0 0 9.845 461.9904 312.718 Tm
[(\(df)-83.8(\))]TJ
/F5 1 Tf
7.5091 0 TD
(p)Tj
-40.8684 0 TD
(N)Tj
/F6 1 Tf
5.891 0 TD
(%)Tj
/F5 1 Tf
8.0677 0 TD
(N)Tj
/F6 1 Tf
10.0083 0 TD
(%)Tj
/F5 1 Tf
-31.2343 -1.8946 TD
[(Ever)-334.5(had)-332.4(cellulitis?)]TJ
1.002 -1.0135 TD
[(Yes)-4323.7(221)-4327.6(30.6)-6882(25)-8444(14.1)-6381.1(19.35)-335.6(\(1\))]TJ
/F7 1 Tf
45.982 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.5348 -1.0135 TD
[(No)-4655.7(502)-4327.6(69.4)-6381.1(152)-8445(85.9)]TJ
-1.002 -1.313 TD
[(Total)-4752.7(723)-12458.7(177)]TJ
0 -1.0135 TD
[(Acute)-336.5(infection)-334.3(in)-336.2(the)-332.6(last)-333.6(year?)]TJ
1.002 -1.0135 TD
[(Yes)-4323.7(143)-4327.6(19.8)-6882(14)-8945(7.9)-6380.1(13.90)-335.6(\(1\))]TJ
/F7 1 Tf
45.982 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.5348 -1.0077 TD
[(No)-4655.7(580)-4327.6(80.2)-6381.1(163)-8445(92.1)]TJ
-1.002 -1.3187 TD
(Number)Tj
1.002 -1.0135 TD
[(1)-5874.7(8)0(4)-4326.6(58.7)-7383(9)-8443(64.3)]TJ
0 -1.0077 TD
[(2)-5874.7(3)0(3)-4326.6(23.1)-7383(3)-8443(21.4)]TJ
0 -1.0135 TD
[(3)-5874.7(1)0(1)-4827.6(7.7)-7382(1)-8944(7.1)]TJ
T*
[(4)-6375.7(7)-4826.7(4.9)-7382(0)-8944(0)]TJ
T*
[(5)-6375.7(5)-4826.7(3.5)-7382(1)-8944(7.1)]TJ
/F7 1 Tf
0 -1.0077 TD
(>)Tj
/F5 1 Tf
.5528 0 TD
[(5)-5822.9(3)-4826.7(2.1)-7382(0)-8944(0)]TJ
-1.5548 -1.3187 TD
[(Total)-4752.7(723)-12458.7(177)]TJ
0 -1.0077 TD
[(Hospitalized)-339.2(in)-330.4(the)-338.3(last)-333.6(year?)]TJ
1.002 -1.0135 TD
[(Yes)-4824.7(73)-4326.6(10.1)-6882(11)-8945(6.2)-6881.1(2.53)-334.6(\(1\))-4874.7(0.11)]TJ
T*
[(No)-4655.7(650)-4327.6(89.9)-6381.1(166)-8445(93.8)]TJ
-1.002 -1.3129 TD
(Number)Tj
1.002 -1.0135 TD
[(1)-5874.7(5)0(8)-4326.6(79.5)-7383(8)-8443(72.7)]TJ
T*
[(2)-5874.7(1)0(0)-4326.6(13.7)-7383(1)-8944(9.1)]TJ
T*
[(3)-6375.7(3)-4826.7(4.1)-7382(1)-8944(9.1)]TJ
/F7 1 Tf
0 -1.0077 TD
(>)Tj
/F5 1 Tf
.5528 0 TD
[(3)-5822.9(2)-4826.7(2.7)-7382(1)-8944(9.1)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(192)Tj
43.8494 0 TD
[(NRREGAARD)-333.5(ET)-338.7(AL.)]TJ
ET
endstream
endobj
62 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 436.6487 Tm
0 0 0 rg
0 Tc
0 Tw
[(Random)-340.5(sample)-332.5([inpatient)-336.4(population)]TJ
/F13 1 Tf
18.4186 0 TD
(N)Tj
/F7 1 Tf
.8915 0 TD
(=)Tj
/F3 1 Tf
.7208 0 TD
(116/177)Tj
-20.031 -1.2203 TD
(\(65.5%\)])Tj
/F5 1 Tf
9.843 0 0 9.843 69.7323 409.266 Tm
[(Data)-307.2(from)-305.1(the)-304.1(random)-302.7(sample)-303.8(from)-305.1(the)-304.1(hospital)-303.9(inpatient)]TJ
-1.0137 -1.1174 TD
[(service)-253(indicated)-249.9(that)-247.7(47/116)-242.9(\(41%\))-248.4(lived)-248.8(alone,)-247.5(with)-247.4(56/116)]TJ
0 -1.1116 TD
[(\(48%\))-202.3(owning)-197.7(their)-202.7(own)-200(property.)-203.5(Not)-200.1(surprisingly,)-200.9(given)-196.9(the)]TJ
T*
[(age)-518.2(of)-514.8(the)-517.2(sample,)-520.4(69%)-517(were)-520.2(retired)-517.1(with)-518.1(only)-511.4(5%)-515.9(not)]TJ
0 -1.1174 TD
[(working)-279.4(due)-269.4(to)-273(illness.)-277.3(However,)-280.1(10%)-269.3(stated)-279.7(that)-270.8(the)-275.3(family)]TJ
0 -1.1116 TD
[(income)-229.2(had)-223.3(been)-225.6(affected)-232.4(by)-226.8(having)-221(CO,)-226.4(irrespective)-231.1(of)-226.8(their)]TJ
T*
[(working)-302.4(status.)-299.1(The)-293.6(majority)-299.5(were)-301.3(dened)-302.5(as)-296.9(having)-295.9(pitting)]TJ
T*
[(edema)-286.7(with)-282(limb)-282.4(shape)-278.3(distortion)-282(evident)-286.8(in)-278.8(32%.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 309.5999 Tm
[(Feasibility)-338.2(of)-336.7(the)-328.5(methods)]TJ
/F5 1 Tf
9.843 0 0 9.843 69.7323 293.159 Tm
[(The)-201.5(study)-195.5(provided)-200.1(important)-202.7(insights)-198.9(into)-194.7(undertaking)-199(the)]TJ
-1.0137 -1.1116 TD
[(study)-293.4(in)-284.6(diverse)-292.2(settings.)-289.9(Changes)-293.1(in)-290.3(education)-290.1(for)-285.5(the)-292.6(main)]TJ
T*
[(study)-281.9(were)-284(made)-278.7(and)-280.9(this)-280.9(included)-276.3(devel)-8(oping)-276.3(a)-278.7(short)-281.9(video)]TJ
0 -1.1174 TD
[(to)-491.9(assess)-486.2(pitting)-492(edema,)-486(performing)-491.5(a)-486.1(Stemmer)-490.5(test,)-487.1(and)]TJ
0 -1.1116 TD
[(measuring)-226.5(the)-217.7(limb)-219(for)-216.3(shape)-226.5(distortion.)-216.3(Quality)-223.2(mechanisms)]TJ
T*
[(for)-343.1(ensuring)-338.2(quality)-343.3(data)-335.2(were)-341.6(effective)-348.8(and)-338.5(integrated)-343.2(into)]TJ
T*
[(the)-580.6(study)-581.4(standard)-581.3(operating)-582.7(procedures.)-587.9(The)-581.6(validation)]TJ
0 -1.1174 TD
[(process)-314.9(reinforced)-314(the)-315.6(hypothesis)-311.6(that)-311.1(classication)-318.4(of)-313.2(lym-)]TJ
0 -1.1116 TD
[(phedema)-306.2(as)-302.7(primary)-303.9(and)-304(secondary)-306.9(lymphedema)-305.1(is)-301.6(difcult)]TJ
T*
[(even)-289(when)-288.7(there)-284.4(is)-284.4(access)-287.3(to)-284.6(trained)-292.5(lymphologists)-286.4(and)-286.7(can-)]TJ
0 -1.1174 TD
[(not)-279.9(be)-285.6(performed)-284.1(reliably)-282.2(in)-278.8(primary)-280.9(care)-284.3(settings.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 160.6676 Tm
(Discussion)Tj
/F5 1 Tf
9.843 0 0 9.843 69.7323 144.2267 Tm
[(The)-293.6(high)-292.5(prevalence)-293.4(of)-295.9(39%)-292.4(of)-290.2(hospital)-292.4(inpatients)-295.9(suffer-)]TJ
-1.0137 -1.1116 TD
[(ing)-199.3(from)-195.6(CO)-199.9(has)-200.1(not)-193.5(been)-202.6(reported)-201.3(before)-198.9(and)-194.5(indicates)-203.7(that)-195.9(it)]TJ
T*
[(is)-370.8(an)-372(important)-375.5(problem)-373.1(in)-370.9(hospital)-367.3(settin)-8(gs)-370.6(and)-367.3(is)-370.8(accom-)]TJ
0 -1.1174 TD
[(panied)-320.1(by)-313.2(a)-313.3(range)-318.8(of)-313.2(comorbidities.)-321.1(As)-313.9(admission)-317.4(was)-321.9(gen-)]TJ
0 -1.1116 TD
[(erally)-222.3(unrelated)-221(to)-215.4(CO,)-220.7(one)-217.6(might)-220.1(consider)-218.4(that)-218.9(these)-220.9(patients)]TJ
T*
[(would)-380.9(be)-377.7(suffering)-373.8(from)-379.9(a)-376.6(mild)-374.5(condition,)-377.8(which)-382.1(does)-374(not)]TJ
0 -1.1174 TD
[(require)-355.7(treatment.)-352.5(However,)-355(evidence)-353.4(from)-351.1(this)-350(study)-351(indi-)]TJ
0 -1.1116 TD
[(cates)-199(that)-195.9(this)-194.5(is)-192.2(not)-193.5(the)-194.7(case.)-195.4(These)-193.1(patients)-201.4(were)-191.9(elderly)-200.3(with)]TJ
T*
[(a)-434.2(range)-434(of)-434.1(comorbidities)-432.9(that)-432(might)-433.2(predispose)-439.3(them)-433.1(to)-428.5(a)]TJ
25.5097 38.5497 TD
[(chronic)-413.3(and)-413.4(severe)-418.8(predisposition)-419.9(and)-413.4(the)-413.5(development)-420.3(of)]TJ
0 -1.1174 TD
[(infection)-283.3(and)-280.9(other)-283.2(issues)-278(that)-282.3(characterize)-292.3(poor)-280.8(outcome.)]TJ
1.0137 -1.1116 TD
[(Comparison)-423.3(between)-421.1(this)-419.2(group)-425.9(and)-419.2(a)-422.7(group)-420.2(who)-418.9(were)]TJ
-1.0137 -1.1116 TD
[(receiving)-307.4(care)-307.4(from)-299.3(a)-307.5(variety)-304(of)-301.7(specialist)-308.4(lymphedema)-310.9(ser-)]TJ
T*
[(vices)-307.3(and)-304(primary)-303.9(care)-307.4(services)-305.8(has)-303.8(identied)-306.2(not)-302.9(only)-304(sim-)]TJ
0 -1.1174 TD
[(ilarities)-490.7(but)-481.5(also)-489.3(several)-489.2(differences.)-492.3(As)-486.7(an)-487.2(example,)-488.3(the)]TJ
0 -1.1116 TD
[(inpatient)-197.1(group)-195.5(experienced)-202.3(fewer)-198.7(acute)-199.2(infections)-203.6(than)-195.8(those)]TJ
T*
[(managed)-283.1(by)-278.7(the)-281.1(lymphedema)-282.1(services.)-286.1(However,)-280.1(when)-282.9(they)]TJ
0 -1.1174 TD
[(did)-308.7(develop)-315.4(an)-308.6(infection,)-315.5(it)-307.7(more)-312(frequently)-313(led)-309.9(to)-313.3(hospital-)]TJ
0 -1.1116 TD
[(ization.)-336.4(It)-336.4(is)-336.2(difcult)-338.5(to)-330.6(know)-339.3(quite)-335.2(why)-332.5(this)-338.5(is)-336.2(so,)-333.7(but)-337.5(it)-330.8(is)]TJ
T*
[(perhaps)-395.7(indicative)-400.9(of)-393.8(patients)-403(within)-393.8(the)-396.2(lymphedema)-403(ser-)]TJ
0 -1.1174 TD
[(vices)-330.3(being)-335.1(managed)-335(more)-335.1(effectively)-339.6(without)-331.5(the)-332.9(need)-335(for)]TJ
0 -1.1116 TD
[(hospital)-280.9(admissions.)]TJ
1.0137 -1.1116 TD
.1743 Tc
[(A)195.4(n)196.2(o)190.5(t)196.1(h)196.2(e)189.3(rk)196.2(e)195.1(y).4(e)189.3(l)196.1(e)195.1(m)195(e)189.3(n)196.2(to)196.2(fr)190.5(i)196.1(s)190.7(ki)196.1(st)196.1(h)190.5(a)195.1(to)196.2(fp)190.5(o)196.2(o)190.5(rm)195(o)196.2(b)196.2(i)190.3(l)196.1(i)190.3(t)196.1(y)196.2(.F)196.4(r)190.5(o)196.2(mt)196.1(h)190.5(e)]TJ
-1.0137 -1.1116 TD
-.0214 Tc
[(dat)-5.3(a)-.6(,)-226.4(i).4(t)-230(i).4(s)-223.9(c)-6.4(lea)-6.4(r)-224.1(th)-5.2(at)-224.2(i)-5.4(mmob)-5.2(ili)-5.3(ty)-224.1(w)-6.1(a)-.6(s)-223.9(c)-6.4(ite)-6.4(d)-224.1(a)-.6(s)-229.7(a)-225.3(cau)-5.2(se)-225.2(o)-5.2(f)-224.1(CO)-230.7(mor)-5.2(e)]TJ
0 -1.1174 TD
-.0217 Tc
[(fr)-5.5(equ)-5.5(e)-.9(nt)-5.6(ly)-264.7(i)-5.6(n)-264.7(t)-5.6(hos)-5.3(e)-265.9(a)-.9(d)-5.5(m)-1(it)-5.7(ted)-270.5(t).1(o)-270.5(hos)-5.3(pit)-5.7(a)-.9(l)-270.6(t).1(ha)-6.7(n)-264.7(t).1(h)-5.5(o).2(s)-5.3(e)-265.9(in)-270.5(ded)-5.5(i).1(ca)-6.7(ted)]TJ
0 -1.1116 TD
-.0215 Tc
[(lym)-6.5(phe)-6.5(dem)-6.5(a)-248.4(s)-5.1(e)-.7(rv)-5.3(ice)-6.5(s).6(.)-249.6(A)-6.2(gai)-5.4(n).4(,)-249.6(i)-5.5(t)-247.4(i)-5.5(s)-252.8(h).4(ar)-5.3(d)-247.2(t)-5.4(o)-247.2(b)-5.3(e)-248.4(p)-5.3(re)-6.5(cis)-5.1(e)-248.4(o)-5.3(n)-247.2(w)-6.2(h).4(at)-253.1(is)]TJ
T*
-.0177 Tc
[(o)4.2(c)3.1(cu)4.2(rr)4.3(i)4.1(n)-1.5(g)4.2(,)-337.9(bu)4.2(t)-341.5(t)4.1(h)4.2(i)-1.6(s)-335.4()-1.3(t)4.1(s)-341.1(t)4.1(h)4.2(e)-342.5(p)4.2(ro)4.2(l)4.1(e)-336.7(o)-1.5(f)-341.3(a)-336.7(mor)4.3(e)-342.5(el)4.1(der)4.3(l)-1.6(y)-335.6(i)-1.6(mmo)4.3(bi)4.1(l)4.1(e)]TJ
0 -1.1174 TD
-.0215 Tc
[(pop)-5.3(ul)-5.4(ati)-5.5(o).4(n)-172.4(r).5(ec)-6.5(eiv)-5.3(i).3(ng)-172.3(su)-5.3(bop)-5.3(ti)-5.4(mal)-172.5(car)-5.3(e)-167.8(i)-5.4(n)-166.6(t)-5.4(he)-167.8(c)-6.5(o).4(mm)-6.5(uni)-5.4(ty.)-168.9(C)-6.3(lea)-6.5(r).5(l)-5.5(y).4(,)]TJ
0 -1.1116 TD
-.0217 Tc
[(thi)-5.7(s)-258.7(i)-5.6(s)-258.8(s)-5.3(p).2(e)-6.7(c)-.9(ul)-5.7(ati)-5.7(on,)-261.3(w)-6.4(h).2(ic)-6.7(h)-258.9(r)-5.5(equ)-5.5(i).1(re)-6.7(s)-258.7(f)-5.5(ur)-5.5(the)-6.7(r)-258.9(i)-5.6(nve)-6.7(sti)-5.6(g).2(at)-5.6(io)-5.5(n.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 202.4503 Tm
0 Tc
(Limitations)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 186.0094 Tm
[(The)-259.1(study)-264.6(has)-263.5(some)-265.8(limitations)-262.8(that)-265(must)-264.8(be)-262.6(addressed.)-269.8(In)]TJ
-1.0137 -1.1116 TD
[(particular,)-317.8(the)-309.9(participants)-316.5(recruited)-318.9(from)-310.8(community-based)]TJ
T*
[(lymphedema)-305.1(services)-305.8(and)-304(primary)-303.9(care)-301.6(nursing)-307.1(services)-305.8(are)]TJ
0 -1.1174 TD
[(unlikely)-217.7(to)-221.2(be)-216.5(representative)-228.7(of)-215.3(the)-223.5(total)-220.2(population)-219.9(receiving)]TJ
0 -1.1116 TD
[(care)-290.1(within)-290.1(this)-286.7(service,)-291(leading)-292.5(to)-284.5(a)-290.2(selection)-290.1(bias.)-291.2(This)-287.8(led)]TJ
T*
[(the)-379(LIMPRINT)-382.4(study)-374.1(team)-382.5(to)-376.7(develop)-378.8(specic)-379.6(methods)-384.4(to)]TJ
0 -1.1174 TD
[(recruit)-304(for)-302.7(community)-307.5(studies)-308.3(to)-301.8(increase)-307.1(reliability)-308.9(and)-304(va-)]TJ
0 -1.1116 TD
[(lidity.)-281.3(These)-279.5(have)-283.2(been)-283.2(reported)-281.9(separately.)]TJ
7.3823 0 0 6.5614 484.3841 113.6693 Tm
(9)Tj
/F3 1 Tf
8.9663 0 0 8.9663 310.8472 83.9622 Tm
(Conclusion)Tj
/F5 1 Tf
9.843 0 0 9.843 320.8251 67.5212 Tm
[(This)-270.5(initial)-280.2(validation)-273(study)-276.1(highlighted)-278.7(opportunities)-275(and)]TJ
-1.0137 -1.1116 TD
[(challenges)-568.7(associated)-574.2(with)-570(undertaking)-573.4(LIMPRINT)-566.7(in)-566.8(a)]TJ
ET
59.754 719.49 490.167 .22668 re
f
59.754 472.819 490.167 .28345 re
f
146.665 700.611 70.072 .22681 re
f
254.835 700.611 151.143 .22681 re
f
59.754 682.923 490.167 .22675 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 158.9669 725.1588 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(5.)Tj
/F9 1 Tf
1.2496 0 TD
[(Treatments)-335.3(for)-338(Lymphedema)-337.3(and)-332(Control)-331.2(of)-337(Swelling)]TJ
/F6 1 Tf
-3.1096 -1.8427 TD
[(LPCS)-7895.2(Hospital)-331.6(inpatient)-339(prevalence)]TJ
/F12 1 Tf
28.3205 -1.8197 TD
(v)Tj
/F5 1 Tf
7.3837 0 0 6.5625 453.94 693.5242 Tm
(2)Tj
/F6 1 Tf
9.845 0 0 9.845 460.9133 689.1022 Tm
[(\(df)-83.8(\))]TJ
/F5 1 Tf
7.2212 0 TD
(p)Tj
-38.7492 0 TD
(N)Tj
/F6 1 Tf
5.4361 0 TD
(%)Tj
/F5 1 Tf
7.4804 0 TD
(N)Tj
/F6 1 Tf
9.5534 0 TD
(%)Tj
/F5 1 Tf
-31.6893 -1.8946 TD
[(None)-6662.8(124)-3867(17.1)-5799.4(130)-8237.7(73.5)-5799.4(222.5)-335.6(\(1\))]TJ
/F7 1 Tf
46.65 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-47.2028 -1.0135 TD
[(At)-337(least)-335.7(one)-3868.1(599)-3867(82.9)-6300.4(47)-8236.7(26.6)]TJ
0 -1.0077 TD
[(Total)-6704.8(723)-11416.4(177)]TJ
0 -1.0135 TD
[(Multilayer)-336.2(bandaging)]TJ
1.002 -1.0135 TD
[(Present)-4880.8(312)-3867(43.2)-6300.4(12)-8737.7(6.8)-6299.4(81.6)-334.6(\(1\))]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.2008 -1.0135 TD
[(Absent)-4994.8(411)-3867(56.9)-5799.4(165)-8237.7(93.2)]TJ
-1.002 -1.313 TD
[(Total)-6704.8(723)-11416.4(177)]TJ
0 -1.0135 TD
[(Compression)-336.5(garment)]TJ
1.002 -1.0135 TD
[(Present)-4880.8(453)-3867(62.7)-6300.4(40)-8236.7(22.6)-6300.4(92.1)-334.6(\(1\))]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.2008 -1.0077 TD
[(Absent)-4994.8(270)-3867(37.4)-5799.4(137)-8237.7(77.4)]TJ
-1.002 -1.3187 TD
[(Total)-6704.8(723)-11416.4(177)]TJ
0 -1.0077 TD
(Massage)Tj
1.002 -1.0135 TD
[(Present)-5381.8(38)-4367(5.3)-6800.4(0)-8736.7(0.0)]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
7.3837 0 0 6.5625 546.6329 549.2975 Tm
(a)Tj
9.845 0 0 9.845 69.6189 534.9542 Tm
[(Absent)-4994.8(685)-3867(94.7)-5799.4(177)-7736.7(100)]TJ
-1.002 -1.313 TD
[(Total)-6704.8(723)-11416.4(177)]TJ
0 -1.0135 TD
[(Control)-336.5(of)-336(swelling)]TJ
1.002 -1.0135 TD
[(Yes)-6275.8(469)-3867(66.7)-6300.4(35)-8236.7(19.9)-5799.4(126.2)-335.6(\(1\))]TJ
/F7 1 Tf
45.648 0 TD
(<)Tj
/F5 1 Tf
.5528 0 TD
(0.001)Tj
-46.2008 -1.0135 TD
[(No)-6607.9(234)-3867(33.3)-5799.4(141)-8237.7(80.1)]TJ
-1.002 -1.3129 TD
[(Total)-6704.8(703)-11416.4(176)]TJ
6.5633 0 0 5.8334 67.748 464.9385 Tm
(a)Tj
8.7511 0 0 8.7511 70.696 461.0267 Tm
[(Fishers)-334.2(exact)-333.3(test.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(VALIDATION)-340.4(STUDY)-335.9(FOR)-334(LIMPRINT)]TJ
53.0113 0 TD
(193)Tj
ET
endstream
endobj
66 0 obj
<>stream
hbd`ad`ddruwvL)010ws4 f!#wˣY;w^.Ș_PYQ`hii$J
Jr23RS*2KKRs<srRSRSyi)y%9zHF}fFF&Vmk~NG?ߵپLffw؏:l| ˏK?
endstream
endobj
69 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(different)-329.2(health)-326(setting.)-323.5(It)-319.1(led)-327.1(to)-324.9(improvements)-323.3(in)-324.9(the)-321.4(study)]TJ
0 -1.1174 TD
[(methodology)-216.4(and)-217.6(quality)-216.6(mechanisms.)-221.7(The)-213(hospital)-217.5(inpatient)]TJ
0 -1.1116 TD
[(study)-247.3(showed)-250.4(the)-246.5(difculty)-247.4(of)-244.1(gaining)-251(consent)-246.1(and)-246.4(accessing)]TJ
T*
[(patients)-328.1(in)-319.1(busy)-321(hospital)-327(settings.)-324.4(Nevertheless,)-327.3(in)-319.1(those)-323.4(re-)]TJ
T*
[(cruited,)-359.3(the)-361.7(prevalence)-362.5(of)-359.3(39%)-355.7(is)-359.2(the)-355.9(highest)-360.3(yet)-361.7(recorded.)]TJ
0 -1.1174 TD
[(Comparison)-250.5(of)-244.1(participant)-252.2(proles)-244.8(between)-248.4(the)-246.5(inpatient)-248.9(and)]TJ
0 -1.1116 TD
[(other)-381.1(lymphedema)-385.7(specialist)-383.3(services)-380.6(and)-384.6(primary)-378.8(care)-382.2(re-)]TJ
T*
[(veals)-290(a)-290.2(complex)-287.9(picture)-292.5(of)-290.2(comorbidities)-294.6(that)-288(have)-289(been)-289(ex-)]TJ
0 -1.1174 TD
[(amined)-281(further)-285.4(in)-278.8(other)-283.2(LIMPRINT)-284.5(studies.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 615.5715 Tm
(Acknowledgments)Tj
/F5 1 Tf
9.843 0 0 9.843 72 599.1306 Tm
[(The)-316.7(authors)-314(would)-317.5(like)-316.8(to)-319.1(thank)-312.1(all)-321.5(the)-315.6(staff)-317.6(and)-315.5(patients)]TJ
-1.0137 -1.1174 TD
[(who)-280.6(made)-284.4(this)-280.9(study)-281.9(possible.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 566.2487 Tm
[(Author)-338.7(Disclosure)-330.4(Statement)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 549.8077 Tm
[(No)-279.5(competing)-284.4(nancial)-283.1(interests)-282.9(exist.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 527.8676 Tm
(References)Tj
/F5 1 Tf
9.2951 0 0 9.2951 62.022 511.8235 Tm
[(1.)-500.4(Moffatt)-251.9(CJ,)-254.3(Franks)-253.4(PJ,)-252.4(Doherty)-252.5(DC,)-256.8(Williams)-256.2(AF,)-248.8(Badger)-254.3(C,)]TJ
1.2503 -1.1284 TD
[(Jeffs)-544.5(E,)-544.9(Bosanquet)-549.8(N,)-544.6(Mortimer)-544.4(PS.)-542.9(Lymphoedema:)-551.6(An)]TJ
0 -1.1223 TD
[(underestimated)-298.7(health)-288.7(problem.)-293.3(Q)-294.5(J)-292(Med)-290.6(2003;)-292.9(96:731738.)]TJ
-1.2503 -1.1284 TD
[(2.)-500.4(Disipio)-408.6(T,)-404.7(Rye)-405.9(S,)-405.7(Newman)-414.6(B,)-401.4(Hayes)-412.4(S.)-405.7(Incidence)-410.2(of)-405.2(uni-)]TJ
1.2503 -1.1223 TD
[(lateral)-374.1(arm)-372.5(lymphoedema)-378.7(after)-373.1(breast)-370(cancer:)-379.4(A)-373.8(systematic)]TJ
0 -1.1284 TD
[(review)-335.9(and)-334(meta-analysis.)-340.4(Lancet)-338.1(Oncol)-335.3(2013;)-329.5(14:500515.)]TJ
-1.2503 -1.1223 TD
[(3.)-500.4(Moffatt)-410.5(CJ,)-406.8(Keeley)-404.8(V,)-410.4(Franks)-405.9(PJ,)-404.9(Rich)-411.5(A,)-404.3(Pinnington)-405.2(LL.)]TJ
1.2503 -1.1284 TD
[(Chronic)-438.7(oedema:)-433.5(A)-434.8(prevalent)-442(problem)-433.5(for)-438.1(UK)-430.4(health)-441.2(ser-)]TJ
0 -1.1223 TD
[(vices.)-337.1(Int)-331.5(J)-334.7(Wounds)-333.7(2017;)-335.6(14:772781.)]TJ
-1.2503 -1.1284 TD
[(4.)-500.4(Boza)-245.5(JC,)-248.2(Trindade)-245(EN,)-247.8(Peruzzo)-244.5(J,)-249.4(Sachett)-247.2(L,)-240(Rech)-251.6(L,)-240(Cestari)]TJ
1.2503 -1.1223 TD
[(TF.)-468.7(Skin)-460.3(manifestations)-469.9(of)-466.1(obesity:)-466.3(A)-471.3(comparative)-464.4(study.)]TJ
0 -1.1284 TD
[(J)-334.7(Eur)-334(Acad)-333.8(Dermatol)-335.2(Venereol)-340.4(2012;)-335.6(26:12201223.)]TJ
25.7571 35.3329 TD
.0184 Tc
[(5)-6.1(.)-500.1(Moffatt)-383.7(CJ,)-384.2(A)-1.6(ubeel)-5.6(uck)-384.3(A)-1.6(,)-384.2(F)-2.9(ranks)-383.4(PJ,)-384.2(D)-1.6(oherty)-384.3(D)-1.6(C,)-384.2(Mo)-6.1(r-)]TJ
1.293 -1.1223 TD
.019 Tc
[(timer)-288.4(P,)-286(Quere)-284.2(I)-1.8(.)-286(P)-2.3(sychologi)-5(cal)-285.5(f)-1.8(actors)-285.2(i)-5(n)-286.1(chroni)-5(c)-284.2(o).6(edem)-5.1(a)]TJ
0 -1.1284 TD
.0192 Tc
[(\(CO\):)-328(A)-324.1(cas)-4.5(e)2.7(-control)-328(S)4(t)-4.8(udy.)-328.5(Lymphat)-328(R)2.1(es)-327.7(Biol)-328(20)-5.3(17;)-328(15:)]TJ
0 -1.1223 TD
.0184 Tc
(252261.)Tj
-1.293 -1.1283 TD
0 Tc
[(6.)-500.4(Moffatt)-337.3(CJ,)-339.7(Pinnington)-332(L.)-337.6(HIEC)-334.4(Project)-336.8(Evaluation)-339.4(Report.)]TJ
1.2503 -1.1223 TD
[(Facilitating)-654.2(the)-650.6(development)-653.1(of)-649.1(community)-650(based)-648.7(lym-)]TJ
0 -1.1284 TD
[(phoedema)-306.1(services)-306.5(through)-307.7(clinical)-304.2(education.)-305.6(University)-305.8(of)]TJ
0 -1.1223 TD
[(Nottingham)-554(and)-547.5(Derby)-551.7(Hospitals)-546.4(NHS)-549.3(Foundation)-550.2(Trust)]TJ
0 -1.1284 TD
(2012.)Tj
-1.2503 -1.1223 TD
[(7.)-500.4(Moffatt)-495.9(CJ,)-498.3(Franks)-497.3(PJ,)-490.3(Keeley)-496.3(V,)-495.8(Murray)-496.9(S,)-491.1(Mercier)-498.8(G,)]TJ
1.2503 -1.1284 TD
[(Quere)-257(I.)-252.6(The)-250.5(Development)-252.1(and)-254.7(Validation)-253.1(of)-252.7(the)-248(LIMPRINT)]TJ
0 -1.1223 TD
[(methodology.)-339.8(Lymphat)-335.5(Res)-331.8(Biol)-333.6(2019;)-335.6(17:127134.)]TJ
-1.2503 -1.1284 TD
[(8.)-500.4(Dai)-310.6(M,)-310.5(Sugama)-310.6(J,)-310.4(Tsuchiya)-315(S,)-308.1(Sato)-306(A,)-312.9(Matsumato)-311.5(M,)-310.5(Iuchi)]TJ
1.2503 -1.1284 TD
[(T,)-447.3(Maeba)-439.5(H,)-447(Okuwa)-441.1(M,)-444.7(Sanada)-443.3(H,)-440.9(Moffatt)-447.1(C.)-438(Inter-rater)]TJ
0 -1.1223 TD
[(reliability)-344.3(study)-340.8(of)-338.1(pitting)-340.3(test)-338.2(for)-340.5(oedema)-342.4(evaluation)-341.7(in)-335.2(the)]TJ
0 -1.1284 TD
[(Kanazawa)-726.8(LIMPRINT)-719.5(study.)-713(Lymphoedema)-722.8(Res)-716(Pract)]TJ
0 -1.1223 TD
[(2015;)-335.6(3:17.)]TJ
-1.2503 -1.1284 TD
[(9.)-500.4(Moffatt)-325.1(CJ,)-321.4(Gaskin)-322.4(R,)-322.2(Sykorova)-321.6(M,)-316.6(Dring)-321.2(E,)-325.4(Aubeeluck)-319.9(A,)]TJ
1.2503 -1.1223 TD
[(Franks)-393.7(PJ,)-386.6(Windrum)-384.8(P,)-387.4(Mercier)-395.1(G,)-386(Pinnington)-386.9(L,)-392.5(Quere)-385.1(I.)]TJ
0 -1.1284 TD
[(Prevalence)-521.2(and)-510.9(Risk)-516.2(factors)-512.7(for)-517.4(Chronic)-511.9(Oedema)-514.8(in)-512(UK)]TJ
0 -1.1223 TD
[(Community)-620.1(Nursing)-625.6(Services.)-621.4(Lymphat)-622.1(Res)-618.5(Biol)-620.2(2019.)]TJ
0 -1.1284 TD
[(\(In)-334.4(press\).)]TJ
9.843 0 0 9.843 441.014 483.4203 Tm
[(Address)-337.6(correspondence)-337.8(to:)]TJ
/F6 1 Tf
-1.653 -1.1116 TD
[(Christine)-334.7(J.)-334(Moffatt,)-335.3(PhD,)-337.1(CBE)]TJ
2.4652 -1.1116 TD
[(School)-336.2(of)-336.4(Social)-330.6(Scien)-8(ces)]TJ
-1.2614 -1.1174 TD
[(Nottingham)-341.6(Trent)-334.7(University)]TJ
2.6725 -1.1116 TD
[(50)-330.5(Shakespeare)-338.9(Street)]TJ
-.0461 -1.1116 TD
[(NG1)-339.3(4FQ)-333.7(Nottingham)]TJ
2.3903 -1.1174 TD
[(United)-331.4(Kingdom)]TJ
-7.9311 -2.1253 TD
(E-mail:)Tj
/F5 1 Tf
3.3982 0 TD
(christine.moffatt@ntu.ac.uk)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(194)Tj
43.8494 0 TD
[(NRREGAARD)-333.5(ET)-338.7(AL.)]TJ
ET
endstream
endobj
73 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
75 0 obj
<>stream
hޤUkTT$1)z4g4D%X_ AQ\<g8BHDhHԠ%j\TL#("L$➸zM]s笻{qUR
[ϋdӍQJ ~xi$T9yESC9Sz\TӼmsS89אeօgM9FSrA?I
#u&`څTIvͮ\;PO"KI9駿)qco?rg}>
5)28UGdh)胫_/ Y2@qm绠esѥ~-S(
z.Ԏ0v>)vacm"0a;5mIkzrfoR.ܣH]u{}&:o|RI$_ȞOJ2Ȓ-qv:Hc F'68[?~4>߶t0nQf]=4nAxkBHҫogLeZDy6qP^y١_){:jtB`<`^?O2_#m~tzDܳÜC|S0CԝN5oD\>qImGdoEk[:ٵB^9=,iYʦk}܇7c5忭5]h3lh*]pVJf(OJBLp7a&{LrpiޱRqښfW[9[ -E_5-WPC<,1Ջ:ߨ1y(/5:0(TeXAELO赪P_ǧ1+7;
= =kt8ݶ`<͐!EL90 4?\-Bk{O0xa=nȳW1[ทk_F,g@+."O'XikW:{wU}ry6GPy).u}MMLBh~0H 6$
Dψ@ RD>KD)!QAoֵ.
ϬG!Np،U+|vȮ\6?BQBPMq;Y;KEy絏|$E].W&OӒM3>'6hQ'G8f2 e[<P+#>:d
耵r`8d8!3mwI~]64/HlRRFa}0k|{xtJ3b¼cOXg+u>cmqnZRD&4I1dʳ:xI,qh!+.X\{۰)Y[i_K?>Z.-p#T~R3jwkor]˴w5}-KWmno3A ʜ|[ (x[Vk/LjY!eFGK<ОjhY{2V'Ϋo}ʮ` ^R~.\D)s+H
(r)mz
u+f#_%c!xv= }6$.J6,cu6ud[mHe+{oR{X>$ʵÖ7tPFE^`'/*0 ~DK
endstream
endobj
77 0 obj
<>stream
EFKINB+AdvPSMP10 qO
AdvPSMP10 W ntfsL2e*[O`JXzr|kkpdyd9)Átlbjg:
endstream
endobj
78 0 obj
<>stream
8;Z\7#nDSA%.!pXR.!_#d5+N2H6K\^(rqN=K2[8pD_AmUXklTg#qgjDXZ
;RF+'VD&@6,+"(M$&D%'_%c7_[4mk78@]>mFTF49K@@e;HiX/V&?jMlr,eY)M!Ht&
)YIW4.OC/2e.24e:0,VG3KJFeC?Ise0cn`Me&0Uh8q+4[JC!!1<0+:f\%%JOQ&a8Ih\=I
Z""?@\KH:XA_(6i,o\b'o%6Me%h-n'6k0)W9@B?JhV@4S2FR'4*4kG
endstream
endobj
30 0 obj
<>stream
8;Z\6>7uQB#k\*4b]WcU1WBD&9;%j?a@E-CgfLT!(iO!N39V=LC/Ir;LK`^rTscaF
'tP`@65RR4kct4LX8l6;Z.bt+\?S<*K^&UQO,W,h5V#32nKsoo"DC*3*d+%:pFK@!
Y&B#Uof-6I?^5'$cp1M]ncKq-=ZQuF4+aa@Qo/il]*cN.nuBVh?Yq&hHO.RRqFoO2
PBi9+"S-FqTb(ZSf0a'g$>k4r!Z
d$[]2UPSY:KTu-8cb4>"D&9gqG*jK>BH1,Z?-O^PpYqEE-*q=8I0f,7'b
XadM"!*i*3-3~>
endstream
endobj
43 0 obj
<>stream
8;Z\78J6\!%.sQAb]i2'(Qm(c-$')iT=#=,Au,qHqO_]2G'"NiiT4S^+Va
4[,qoX,DN8'^6SEYmf__Z1-;>j0970^t&d+Ti'%WbuHnBU"dlfqOAm
e\spQZM;]ib?$dj2ZP/-T.9~>
endstream
endobj
50 0 obj
<>stream
8;Z\6>7SOn%-.='b]TdS$kcki_*FjI+/93O*#!"B??d$5Gs]Ld7hu5sH7IO8m!Y8.!$SG6/"P.Bm5&sm_eraN/edW>`0I?([sRK$\k7?SMWIi0
nkoC_9'Tj".+⁡Cg+t^"tj3\mS0N4;d_`;D6R_[4bHp&d:HV!sc^)1Vm,RU6
Gj,,n!dY[R9q9>qeFs(W5ek/SltkOK?i2Q@!s%thMq\~>
endstream
endobj
55 0 obj
<>stream
8;Z\6gD7XK%.jLKOPeH\:=BkTOXlb79=,Bq6R$F\HCp,^?_n31R=]5VQn)+0c\:VP9BJt9,)Lbg
^PQ*!7D4[-:Nf6pqW2X>Lou9jj;Q9QZ5b.M
-_W@Lr^kqbk7L:ld_I0[0N:JTpPJY*:Q,^raT,o-8>#UVH*nBb#chF1#uT5u8?H+1
:.s>KQV308T8.Ms+T^>@]9B"8YJi(ZmsT&fS:iSES+fU,I^s6Mk<0LN519(1hP4=+
p+OX:=S>p(6VR+.1VqlSpZE+7a+%A^Bp`_I_Cf*?E$#)UA,B@~>
endstream
endobj
59 0 obj
<>stream
8;Z]";%eL8#Xl6'"`p6[<*KM40$,G$Xo"kgioYdp[?O05&kUubBaE*78L/6H;P8*%
]2ob_`Uo:Z3O"p?/p?0$nfbB;e9j,!,)AjZ/a)">%O5a7G&VsO/oeC_<1#\n<>)?2
bqUss0WpDUWJT8"?e2EXC>'^9oAr5F2*o2O`83jFhu^
0$juP6J:/?iZa7dpT3@u8=Jk9W@V+aFj"t6n@]U:k&sVjoZoLS!["
bWSn#MI4WXEUTEYEL^+pnmVsd@X)!%>hlb5~>
endstream
endobj
63 0 obj
<>stream
8;Z\6=V??0']]0/I+RV)Q0%B9Ff_![TKlfrQ:c6DJ^WKTkb#Ibfch+@:*_-^Z0@nN
ekD9-pdk:uAa"HJIM.!.A7!fU:TJeZL=O8TRB8*%Mcd-Q0RBh3U0Jri3MfEmM`fZC
>l6YN"DIMg/j:2VF`a/tj>nKk8"r8XiTB^#gK(3n--p)Xl.OAh%V*m(JgbDWc0]k/
l]V!D*$SV8g%cfP:`iT4COI`LI:sL(`PQt2]!BK.,s?$!6A9W?=do+sRG86p;E
m'4Je3KZ%W&.`B&\.gdsI,23A@e5PqVoWX)*6Dt6=21cnZ[IP?YTC@'1c.=`O4I6?6&keK8@_NcU47*MDi38r7h)!Oor&%#m+4Gs*'#PR^K$G7o^kn<">)N0Qa
FU^)nh^6>ldFL>Sq1%Fsn/)/u4W'I~>
endstream
endobj
70 0 obj
<>stream
8;Z\t9+lk2$q#+9$g'KUV3!["5:&Z5H92o@!FX^*]BiThtf2%=)#J[S;IPL6I8]Zt9<-).9L
%/9MQ%(bUmGM-om8/!_BZ2Ec,6unTW`BjjL29CnFb:s)Uhg3?*N_pC`0hjB!HF3
LlJ3,lX1P45,\&AGpC*7MAM#9K!T%CN\TtuQc8jUK73:%?VUH)jYDRS`8d`r7Ie@W
&RtRm="+9X'\Sp[-%lgr#U+j46Mr(#!@it~>
endstream
endobj
82 0 obj
<>
endobj
83 0 obj
<>stream
HTn0+t .28:0bݒX^[
d%AΈr.{f9d
9OxR{Pcjx֟I"ڜK%*T)|E`zADG:B0rЩ+ #'%F
hgTd4Mi{ödvqfB
̙>S%3{Xvt詮kWN ;*_ƄqY@cd۬o"